Introduction {#sec1}
============

Cephalotaxine represents the parent polycyclic core of a series of *Cephalotaxus* alkaloids, which are characterized for containing the 1-azaspiro\[4.4\]nonane ring system. These alkaloids exhibited potent antiproliferative activities against cancer cells.^[@cit1a]−[@cit1c]^ Particularly, homoharringtonine, an ester derivative of cephalotaxine, has been approved for treatment of chronic myeloid leukemia.^[@cit1a],[@cit1b]^ In fact, 1-azaspiro\[4.4\] nonane derivatives are present in several compounds that exhibit marked biological activity, including inhibition of hepatitis C virus^[@cit1d]^ and as agonists of the nicotinic acetylcholine receptors (mAChR).^[@cit1e],[@cit1f]^ From an ionic reactions approach, countless synthetic strategies have been described to build these spirane compounds, some of them compiled in the review of Tietze et al.^[@ref2]^ published in 2004. Others have been reported until the end of 2018;^[@ref3]^ among these, only one research group reports the construction of the aforementioned spirocycle in a single step, using a tandem intramolecular hydroamination/semipinacol rearrangement.^[@ref4]^ On the other hand, in the field of radicals chemistry, there are only four synthetic methodologies reported in the literature: Bowman et al.^[@ref5]^ used a domino bicyclization involving neutral aminyl radicals ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}), while Simpkins et al.,^[@ref6]^ Renaud et al.,^[@cit7a]^ and Taniguchi and Ishisbashi^[@cit7b]^ carried out a synthetic route with alkyl radicals as intermediaries, starting from a pre-existing ring.

![First Approach via Radicals toward the Construction of 1-Azaspiro\[4.4\]nonane Derivatives](ao9b02515_0003){#sch1}

Our research group has been interested in the development of C--N bond-forming methodologies based on nitrogen-centered radical intermediaries using domino strategies to obtain heterocyclic compounds with biological potential. In that sense, we had previously reported a cascade radical bicyclization process involving oxime ethers, where aryl radicals were generated and immediately added onto a C=N bond in order to produce neutral alkoxyaminyl^[@ref8]^ or alkyl-oxyaminyl^[@ref9]^ radicals, which were then subsequently captured by a double bond activated with groups: Ph, CN, or CO~2~Me. This process afforded heterocyclic compounds **5** exhibiting a pyrrolidine nucleus fused to the indene skeleton ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}),^[@ref9]^ whereas 1,5 hydrogen transfer and 6-*exo*-*trig* cyclization occurred to produce the side products **6** and **7**.

![Domino Radical Bicyclization of Oxime Ethers **4** To Produce Heterotricyclic Fused Compounds **5** as Main Products](ao9b02515_0004){#sch2}

On the basis of our research work, Landais et al.^[@ref10]^ in 2008 attempted to obtain 1-azaspiro\[4.4\]nonane derivatives through the sequential formation and capture of neutral alkoxyaminyl radicals onto double bonds, but only monocyclized products were observed because nitrogen-centered radical intermediates underwent a recombination reaction with other carbon-centered radicals generated in the reaction media.

In order to exploit the synthetic potential of this methodology that allowed us to incorporate the nitrogen atom to fused ring systems with biological potential and also to avoid the above-mentioned side reactions, another class of precursors was designed. Thus, we preliminarily synthesized the oxime ether **8** and when radical conditions were applied, the spiro\[indene-1,2′-pyrrolidine\] **9** was obtained as a diastereomeric mixture ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).^[@ref11]^ In this case, during the domino bicyclization process, two rings were formed, connected by a single C atom (quaternary center) to generate the 1-azaspiro\[4.4\]nonane nucleus in a single stage reaction.

![Synthesis of the 1-Azaspiro\[4.4\]nonane Derivative **9** via a Domino Radical Bicyclization](ao9b02515_0005){#sch3}

Therefore, on the basis of our previous research work, and taking into account that the synthetic potential of the alkoxyaminyl radicals has been far less explored, herein, we present a new methodology for the synthesis of 1-azaspiro\[4.4\]nonane-based compounds **19** through a domino radical bicyclization from functionalized oxime ethers involving the formation and capture of alkoxyaminyl radicals.

Results and Discussion {#sec2}
======================

The radical precursors (oxime ethers) were synthetized in a four-stage route. Initially, the alkylation of methyl 3-oxobutanoate (methyl acetoacetate) was carried out on its most basic carbon through a dianion intermediate generating the β-ketoesters **11--15**,^[@ref12]^ which were alkylated on the activated methylene. The carbomethoxy group (−CO~2~Me) of the esters **16a--c** was removed by dealkoxycarbonylation using the Krapcho reaction.^[@ref13]^ Whereas the β-ketoesters **16d--j** reacted under a novel modification^[@ref14]^ to the aforementioned reaction affording ketones **17d--j** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Finally, the ester **16k** was dealkoxycarbonylated using the Curran method^[@ref15]^ and lithium chloride (entry 11, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Then, the **17a--k** compounds were treated with *O*-benzyl hydroxylamine hydrochloride, generating the corresponding *O*-benzyl oxime ethers **8** and **18a--j**, as a mixture of geometric isomers.

###### Synthesis of Oxime Ether Precursors **8** and **18a--j**[a](#t1fn1){ref-type="table-fn"}

![](ao9b02515_0010){#GRAPHIC-d7e397-autogenerated}

![](ao9b02515_0011){#gr10}

Reaction conditions: (a) *t*-BuOK/THF/rt or NaH/THF/reflux; (b) LiCl/H~2~O/DMSO/110--170 °C, SiO~2~/LiCl/DMF/MW or LiCl/H~2~O/DMF/MW (c) BnONH~3~Cl/Py/CHCl~3~ or MeOH/reflux.

Subsequently, the oxime ethers with brominated aromatic rings **18a--b** (entries 1--3, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}) were subjected to radical conditions under inert atmosphere, with Bu~3~SnH/2,2′-azobisisobutyronitrile (AIBN) (Method A) in cyclohexane at reflux between 6 and 8 h. The reaction proceeded affording the spirocycles **19a** (66%) and **19b** (64%) as a pair of diastereomers, which were isolated by column chromatography.

###### Domino Radical Bicyclization Reaction of *O*-Benzyl Oxime Ethers **8** and **18a--e**

![](ao9b02515_0012){#GRAPHIC-d7e456-autogenerated}

                               \(A\)          \(B\)                                                
  --- ---- -------------- ---- -------------- -------------- ------- -------------- -------------- -------
  1   Br   CO~2~Et        H    **19a** (66)   **20a** (24)   59/41                                  
  2   Br   Ph             H    **19b** (64)   **20b** (17)   66/34                                  
  3   Br   Me             Me   **19c** (11)   **20c** (28)                                          
  4   I    CO~2~Et        H    **19a** (58)   **20a** (20)   80/20   **19a** (65)   **20a** (12)   90/10
  5   I    Ph             H    **19b** (56)   **20b** (16)   63/37   **19b** (56)   **20b** (9)    70/30
  6   I    4-ClC~6~H~4~   H    **19d** (20)   **20d** (10)           **19d** (23)   **20d** (13)    
  7   I    Ph             Ph   **19e** (57)   **20e** (16)   100/0   **19e** (50)   **20e** (14)   100/0
  8   I    CN             H    **9** (66)     **10** (10)    69/31   **9** (64)     **10** (13)    78/22

In contrast, for the precursor **18c** bearing the double bond with two methyl groups (electron-releasing nature) (entry 3, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}), the reduction of the intermediate alkoxyaminyl radical predominated affording the monocyclized product **23c** (50%) ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}), with respect to the spirane compound **19c** (11%). This percentage was estimated by nuclear magnetic resonance (NMR) of the crude sample because it was not possible to carry out an effective separation of the expected product. Such behavior demonstrates one more time the nucleophilic nature of such radicals,^[@ref9]^ and then attempting to increase the yield of the desired compound **19c**, MgBr~2~·Et~2~O was used in order to reverse the polarity of the alkoxyaminyl radical and confer it electrophilicity via a complexation reaction with the electron lone pair of the nitrogen atom.^[@ref5]^ Nevertheless, the reaction did not proceed.

![Feasible Stages for the Domino Radical Bicyclization of the Oxime Ethers **18a--g**](ao9b02515_0006){#sch4}

On the other hand, oxime ethers **8** and **18d,e** containing an iodinated aromatic ring were reacted via radicals in cyclohexane, using AIBN at reflux (Method A) and BEt~3~ at room temperature (Method B), with reaction times decreased to 3 h and similar yields in both methods to afford the expected diastereomeric mixture of spirocyclic products (entries 4, 5, 6, 8, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). In all cases (of the double cyclization by radicals) oxime ethers (**10** y **20a--e**) *E* and *Z* were obtained as minor products (9--28%) due to the premature reduction of the aryl radical with Bu~3~SnH ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). It is remarkable that the diastereoselectivity of this reaction increased when triethylborane (Et~3~B) was used, especially in compound **19a** bearing the substituent carboethoxy (CO~2~Et). It is suggested that oxygen atoms could act as Lewis bases forming a voluminous complex with boron and generating greater steric hindrance, which prevents the formation of the *cis* diastereomer.

The *trans*/*cis* configuration assignment of spyrocyclic compounds was carried out on the basis of NOESY-2D experiments, where the couplings of protons showed in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"} allowed to assign the *trans* configuration of one of the diastereomers of **19b** ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02515/suppl_file/ao9b02515_si_001.pdf)). In turn, one of the diastereomers **9** was characterized with the *trans* configuration by X-ray diffraction.^[@ref11]^

![NOESY-2D couplings of the trans diastereomer **19b** (one enantiomer is shown).](ao9b02515_0001){#fig1}

The *cis* and *trans* diastereomers displayed marked differences in the chemical shift of the C**H** at the pyrrolidinic ring and the OC**H**~2~Ph group in the ^1^H NMR spectra. As a general rule, *trans* diastereomers showed these signals at lower field compared to *cis* diastereomers. On the other hand, diastereotopic methylene protons of the benzyloxy groups appeared as two doublets, separated by approximately ∼0.06 and ∼0.38 ppm in the *trans* and *cis* diastereomers, respectively. As shown in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, the *trans* spiranes were always observed as the major products.

In addition, the radical bicyclization of precursor **18g** showed complete diastereoselectivity for the product, spyrocyclic **19e** again in *trans* configuration (entry 7, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}), established by the NOESY-1D experiment. Thus, when selective irradiation was applied on H~β~ proton, a spatial coupling with the protons of the benzyloxy group was noticeable and by selectively irradiating the hydrogens of that group, other coupling was observed with the hydrogens of the cyclopentane ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} and the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02515/suppl_file/ao9b02515_si_001.pdf)).

![NOESY-1D couplings of protons of the trans diastereomer **19e** (one enantiomer is shown).](ao9b02515_0002){#fig2}

Finally, the spirocycle *trans*-**19d** substituted with 4-ClC~6~H~4~ group was isolated at the lowest yield, although the ^1^H NMR spectrum of the crude product showed significant presence of the expected compound as a mixture of *cis* and *trans* diastereomers. The above suggests a decomposition event during the purification process by chromatography (entry 7, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). With respect to precursor **18h** containing the aryl group substituted with a NO~2~ at position 4, the domino cyclization reaction did not proceed.

Based on the above results, as well as previous studies,^[@ref9]^ we reasoned a chain transfer radical for the domino bicyclization reaction, where the halogen atom is abstracted by tributylstannyl radicals from the oxime ethers **8** and **18a--h** to afford aryl radicals **21**. These last underwent an intramolecular 5-*exo*-*trig* closure on the imino function to generate alkoxyaminyl radicals **22**, which were captured intramolecularly by the double bond of the alkenyl moiety to obtain the compounds **19** exhibiting the azaspiro\[4.4\]nonane core ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). Formation of side products **20** and in one case, the monocyclized product **23c** ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}), corroborates the mediation of aryl and alkoxyaminyl radicals **21** and **22**, respectively, in the domino radical bicyclization process.

As shown in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, the domino radical bicyclization led to diastereomeric mixtures of the spirocyclics **19a**, **b**, **e**, and **9** with a predominance of the *trans*-stereoisomer. These results are in agreement with the "Beckwith--Houk *ET* model,"^[@ref16]^ which predicts that the major product arises when the substituent occupies an equatorial position in the pseudo-chair conformation for cyclizations 5-*exo* of 2-substituted 5-hexenyl radicals to give predominantly *trans*-1,3-disubstituted cyclopentanes. Based on this model, in [Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}A, equatorial and axial pseudo-chair conformations of alkoxyaminyl radicals **22b** allow to observe the preference of chair-equatorial conformation before the second cyclization gives rise to *trans* diastereomer **19b**.

![Conformational Equilibrium of the Equatorial and Axial Pseudo-Chairs for the Alkoxyaminyl Radicals **22b** (A) and **22e** (B), To Afford the Corresponding Diastereomeric Spirocyclics *trans* and *cis*-**19b** (A) and *trans*-**19e** (B) (One Enantiomer is Showed)](ao9b02515_0007){#sch5}

On the other hand, the bicyclization of compound **18g** with two phenyl substituents at the end of the olefin part gave rise exclusively to trans stereoisomer **19e**. In this case, the pseudo-chair axial conformation is less stable than the pseudo-chair equatorial. Additionally, the steric hindrance between the phenyl groups and the indenic nucleus preclude the second cyclization. See [Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}B.

In addition, considering the excellent reactivity of vinyl radicals for addition onto the imine function in oxime ethers,^[@ref17],[@ref18]^ two new precursors **18i,j** (entries 9--10, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) were designed including an alkynyl moiety, instead of the 2-halophenyl groups. When the radical conditions were applied to these precursors, only spirocyclic products **25i,j** ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}) were obtained without evidence of reduction products. This behavior either suggests that the rate of the first cyclization could be faster in comparison with aryl radicals and/or that the stannylvinyls radicals are reduced slower than the aryl radical intermediates.

###### Domino Radical Bicyclization Reaction of *O*-Benzyl Oxime Ethers **18i**,**j**

![](ao9b02515_0013){#GRAPHIC-d7e1145-autogenerated}

                \(A\)          \(B\)                  
  --- ---- ---- -------------- ------- -------------- -------
  1   Ph   H    **25i** (66)   53/47   **25i** (45)   65/35
  2   Ph   Ph   **25j** (64)   100/0   **25j** (49)   100/0

A hypothetical pathway could be described by the intermolecular addition of tri-*n*-butylstannyl radicals on the triple bond to afford stannylvinyl radicals **26i,j**, which are added to the oxime function via a 5-*exo*-*trig* closure, generating alkoxyaminyl radicals **27i,j**. These, in turn, are captured by the double bond of the alkenyl moiety in another 5-*exo*-*trig* closure to obtain stannylated spirocycles, **28i,j** ([Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}).

![Suggested Mechanism for the Domino Radical Bicyclization of the Oxime Ethers, **18i,j**](ao9b02515_0008){#sch6}

After removal of cyclohexane, a mixture of silica gel/AcOH/DCM was added to eliminate the tri-*n*-butylstannyl group (dehydrostannylation), achieving the expected spirocyclic products **25i,j** ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}). The diastereomeric pair configuration for the spirocycles **25i** was assigned in the same way as it was done for compounds **19a, b , d, e** (differentiation of doublets between methylenic protons of the benzyloxy group: *trans* = 0.05 ppm and *cis* = 0.2 ppm).

Domino radical bicyclization reaction of *O*-benzyl oxime ether **18i** with AIBN in boiling cyclohexane proceeded with no diastereoselectivity, probably due to the comparable stabilities of both equatorial and axial pseudosilla conformations **27i**, along with the absence of steric hindrance which makes the addition of the alkoxyaminyl radical to the C=C bond in both conformations difficult ([Scheme [7](#sch7){ref-type="scheme"}](#sch7){ref-type="scheme"}). However, it is worth mentioning that these compounds showed a predominance of the *trans* stereoisomer when Et~3~B was used as an initiator (Method B) at room temperature.

![Conformational Equilibrium of the Equatorial and Axial pseudo-chairs for the Alkoxyaminyl Radical, **27i** and Their Capture by the Olefinic Appendix](ao9b02515_0009){#sch7}

Finally, the domino radical bicyclization from oxime ether **18j** resulted in a sole product, which was assigned a *trans* configuration by comparison with the cyclization of the analogous oxime ether **18e** \[[Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}B\].

Unfortunately, it was not possible to differentiate the methylenic hydrogens of the cyclopentane and those of the pyrrolidinic nucleus to achieve a selective irradiation of protons in a NOESY experiment. Here, the high diastereocontrol observed for the stannilated spirocyclic **28j** (R^1^ = R^2^ = Ph) could be explained as described for **28i** ([Scheme [7](#sch7){ref-type="scheme"}](#sch7){ref-type="scheme"}). With **28j** the free movement of the *n*-butyl groups around the tin atom in the transition state would generate steric hindrance with any of the phenyl groups linked to the double bond.

It is noteworthy that this research work, focused on the construction of 1-azaspiro\[4.4\]nonane derivatives, constitutes the second documented approach toward these target compounds via tandem radical bicyclization with better yields than the pioneering work of Bowman et al.^[@ref5]^ Besides, this is the third example in the literature that considers the simultaneous formation of two rings, accounting for both ionic and radical reactions. Another relevant aspect to point out is that the use of Et~3~B as the radical initiator allowed us to perform the synthesis under mild reaction conditions and improved diasteroselectivity.

Conclusions {#sec3}
===========

In summary, we have successfully developed a synthetic methodology to obtain 1-azaspiro\[4.4\]nonane derivatives by a domino radical bicyclization involving aryl/stannylvinyl and alkoxyaminyl radicals. The new spirocyclic compounds **19** and **25** were synthesized in moderate yields as a mixture of diastereomers (in most cases) with predominance of *trans* configuration starting from *O*-benzyl oxime ethers containing a brominated or iodinated aromatic ring or terminal alkynyl group and an alkenyl moiety. Two radical initiators were used: AIBN at reflux and Et~3~B at room temperature. Their comparison shows that the reaction times (3 h) with the Et~3~B initiator are shorter versus 6 h for reactions with AIBN, while diastereoselectivity increases remarkably.

On the other hand, when aryl radicals were present, domino radical bicyclization displayed side products due to their premature reduction. In contrast, in those compounds exhibiting the terminal alkynyl group and generating stannylvinyl radicals, no side products were observed. Furthermore, *O*-benzyl oxime ethers with two phenyl groups linked to the alkenyl moiety displayed complete diastereoselectivity in the domino bicyclization process. Last, but not less important, the obtained compounds with this synthetic methodology are alkoxyamines, which could generate nitroxides (or aminoxyl radicals).^[@ref23]^ Currently, our research group is making efforts to optimize the design and synthesis of other structurally modified alkoxyamines that can be used in nitroxide-mediated radical polymerization.

Experimental Section {#sec4}
====================

General Remarks {#sec4.1}
---------------

Melting points were determined in open capillary tubes on Stuart SMP10. Reactions were monitored by thin layer chromatography (TLC) on 0.2 mm silica gel F~254~ plates (Merck); the spots were visualized under UV light (254 nm). Column chromatography and flash column chromatography were conducted under silica gel (Merck, 70--230 or 230--400 mesh). The chemical structures of intermediate and final products were elucidated by nuclear magnetic resonance spectra (^1^H NMR, ^13^C NMR) which were determined on a Mercury 400 and 500 MHz, Gemini 300, VXR 300, and a Bruker AVANCE II 400 MHz spectrometer; ^13^C NMR spectra are fully decoupled. The ^1^H NMR (400 MHz) and ^13^C NMR (100 MHz) spectra were recorded in CDCl~3~ solution using a chloroform peak (7.24 ppm for ^1^H and 77.0 ppm for ^13^C) as a reference. Elemental analysis was determined on a Thermo FlashEA 1112 series with a CHN analyzer, and high resolution mass spectra (HRMS) was recorded on a Finnigan 4021 with GC coupled Kratos MS-80 and MS-50 using electronic impact, chemistry ionization, or electrospray ionization (ESI). Reagents as potassium *tert*-butoxide, tri-*n*-nubutyltin hydride, azobisisobutironitrile (AIBN), triethylborane (Et~3~B), 1-bromo-2-(bromomethyl)benzene, 1-iodo-2-methylbenzene, 3-bromoprop-1-yne, methyl acetoacetate, 4-iodobut-1-yne, 4-chlorobenzaldehyde, benzylhydroxylamine hydrochloride, cesium fluoride, potassium fluoride, magnesium sulphate, lithium chloride, and the solvents: dichlorometane (DCM), dimethylformamide (DMF), pyridine, toluene, cyclohexane, methanol, chloroform, ethyl acetate, and so forth, were purchased from commercial suppliers (Sigma-Aldrich Chemical Co. or Alpha Aesar). The solvent tetrahydrofuran (THF) was distilled under N~2~ from Na-benzophenone.

General Procedure for the Synthesis of Spirocycles **19a--e**; **9** {#sec4.2}
--------------------------------------------------------------------

Method (A): AIBN as initiator. A round bottom flask was charged with the corresponding oxime ethers (1.0 mmol), tributyltin hydride (1.2 mmol), and AIBN (0.25 mmol) with cyclohexane to reach a 0.02 M solution. The flask was stoppered with a rubber septum, purged with N~2~ or Ar for 30 min, and the contents were placed into a mineral oil bath heated at 90 °C. The reaction mixture was stirred until the substrate was consumed (monitored by TLC). Method (B): Triethylborane as initiator. A round bottom flask was charged with the corresponding oxime ether (1.0 mmol), tributyltin hydride (1.2 mmol), and triethylborane 1.0 M (2.5 mmol) in cyclohexane to reach a 0.02 M solution. The flask was stoppered with a rubber septum and the contents stirred at room temperature until the substrate was consumed (monitored by TLC). After removal of cyclohexane, the residue (in both methods) was dissolved in ethyl acetate (∼3 mL), mixed with ∼2 mL of an aqueous solution of KF or CsF (10%), and stirred overnight. The white solid was filtered, the liquid phase extracted with ethyl acetate, and the combined organic extracts dried with anhydrous magnesium sulphate. Finally, the solvent was removed under reduced pressure and the crude product filtered on a short column charged with a silica gel 70--230 mesh and eluted initially with hexane, then with a solution of toluene/hexane (15%) to remove organotin impurities. After evaporation of the solvent, this crude prepurified was passed over flash column chromatography filled with a silica gel 230--400 mesh or preparative plate to obtain the corresponding spirocyclic compounds **19** and the byproducts **20**.

### *trans*-/*cis*-Ethyl 2-(1′-(Benzyloxy)-2,3-dihydrospiro\[indene-1,2′-pyrrolidin\]-5′-yl)acetate (**19a**) {#sec4.2.1}

Method (A). (97.4 mg, 66%). *cis* diastereomer (40.0 mg, 27%); *trans* diastereomer (57.4 mg, 39%). Compound **19a** was prepared according to the general procedure from oxime ether **18a** (180 mg, 0.41 mmol), tributyltin hydride (120 μL, 0.45 mmol), AIBN (20.0 mg, 0.12 mmol), and cyclohexane (18 mL) during 6 h. The crude product was purified by flash column chromatography, silica gel 60--200 mesh (30--60% DCM, 5% gradient). Method (A). (37.9 mg, 58%): *cis* diastereomer (7.5 mg, 12%); *trans* diastereomer (30.4 mg, 46%). Compound **19a** was prepared according to the general procedure from oxime ether **18d** (87 mg, 0.18 mmol), tributyltin hydride (60 μL, 0.22 mmol), AIBN (7.5 mg, 0.04 mmol), and cyclohexane (8.8 mL) during 3 h. The crude product was purified by preparative plate chromatography (silica gel, 1000 μm, 10 cm × 20 cm) with two elutions with 40% DCM/hexane. Method (B). (47.4 mg, 65%). *trans* diastereomer (42.4 mg, 58%); *cis* diastereomer (5.0 mg, 7%). Compound **19a** was prepared according to the general procedure from oxime ether **18d** (100.0 mg, 0.24 mmol), tributyltin hydride (70 μL, 0.22 mmol), Et~3~B (0.60 mL, 0.60 mmol), and cyclohexane (10.0 mL) during 3 h. The crude product was purified by preparative plate chromatography (silica gel, 1000 μm, 10 cm × 20 cm) with two elutions with 40% DCM/hexane. *trans*-**19a**: yellow oil ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.65 (ddt, 1H, *J* = 12.9, 9.5 y 7.6 Hz), 1.87--1.94 (m, 1H), 2.00 (ddd, 1H, *J* = 13.1, 10.1 y 4.5 Hz), 2.05--2.13 (m, 2H), 2.45 (ddd, 1H, *J* = 13.0, 7.0 y 2.0 Hz), 2.67 (dd, 1H, *J* = 13.0 y 9.4 Hz), 2.80 (ddd, 1H, *J* = 16.1, 8.7 y 2.7 Hz), 3.10 (dd, 1H, *J* = 16.0 y 7.5 Hz), 3.12 (dd, 1H, *J* = 10.0 y 7.5 Hz), 3.65 (tdd, 1H, *J* = 9.3, 8.2 y 4.8 Hz), 4.44 (d, 1H, *J* = 10.7 Hz), 4.51 (d, 1H, *J* = 10.7 Hz), 7.02--7.05 (m, 2H), and 7.05--7.30 (m,12 H); ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 27.3, 30.8, 34.2, 39.0, 41.3, 68.1, 77.6, 79.0, 124.5, 125.4, 126.1, 126.1, 127.7, 128.3, 128.43, 128.7, 129.4, 137.7, 140.2, and 145.6. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~26~H~27~NONa, 392.1985; found, 392.1971. *cis*-**19a**: yellow oil ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.58--1.65 (m, 1H), 1.70--1.84 (m, 3H), 2.00--2.16 (m, 1H), 2.70 (dd, 1H, *J* = 13.0 y 6.0 Hz), 2.65--2.77 (m, 1H), 2.86 (ddd, 1H, *J* = 15.6, 8.8, 5.2 Hz), 3.02 (ddd, 1H, *J* = 15.6, 8.8, 6.0 Hz), 3.20 (dd, 1H, *J* = 13.0 y 4.0 Hz), 3.31--3.41 (m, 1H), 4.04 (d, 1H, *J* = 10.2 Hz), 4.43 (d, 1H, *J* = 10.2 Hz), 6.94--6.98 (m, 2H), 7.20--7.30 (m, 11H), and 7.51--7.54 (m, 1H). ^13^C NMR (DMSO-*d*~6~, 100 MHz): δ (ppm) 24.2, 29.8, 29.9, 33.5, 40.3, 64.8, 76.7, 77.0, 123.6, 124.2, 125.8, 126.2, 127.5, 127.9, 128.1, 128.4, 128.9, 136.9, 139.3, 144.0, and 145.7. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~26~H~27~NONa, 392.1985; found, 392.1967.

### *trans*-/*cis*-5′-Benzyl-1′-(benzyloxy)-2,3-dihydrospiro\[indene-1,2′-pyrrolidine\] (**19b**) {#sec4.2.2}

Method (A). Yellow oil (106.0 mg, 64%). *cis* diastereomer (36.0 mg, 23%); *trans* diastereomer (70.0 mg, 41%). Compound **19b** was prepared according to the general procedure from oxime ether **18b** (156.0 mg, 0.42 mmol), tributyltin hydride (129.0 μL, 0.47 mmol), AIBN (23.0 mg, 0.13 mmol), and cyclohexane (21.0 mL) during 6 h. The crude product was purified by column chromatography, silica gel 60--200 mesh (15--25% DCM, 5% gradient). Method (A). (41.6 mg, 56%). *cis* diastereomer (15.3 mg, 21%); *trans* diastereomer (26.3, 36%). Compound **19b** was prepared according to the general procedure from oxime ether **18e** (101.0 mg, 0.20 mmol), tributyltin hydride (66 μL, 0.24 mmol), AIBN (8.4 mg, 0.05 mmol), and cyclohexane (10.0 mL) during 3 h. The crude product was purified by preparative plate chromatography (silica gel, 1000 μm, 10 cm × 20 cm) with two elutions with 30% DCM/hexane. Method (B). (45.4 mg, 56%). *cis* diastereomer (13.7 mg, 17%); *trans* diastereomer (31.7 mg, 39%). Compound **19b** was prepared according to the general procedure from oxime ether **18e** (110.0 mg, 0.20 mmol), tributyltin hydride (71 μL, 0.26 mmol), Et~3~B (0.55 mL, 0.55 mmol), and cyclohexane (10.0 mL) during 3 h. The crude product was purified by preparative plate chromatography (silica gel, 1000 μm, 10 cm × 20 cm) with two elutions with 30% dichloromethane/hexane. *trans*-**19b**: yellow oil ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.65 (ddt, 1H, *J* = 12.9, 9.5 y 7.6 Hz), 1.87--1.94 (m, 1H), 2.00 (ddd, 1H, *J* = 13.1, 10.1 y 4.5 Hz), 2.05--2.13 (m, 2H), 2.45 (ddd, 1H, *J* = 13.0, 7.0 y 2.0 Hz), 2.67 (dd, 1H, *J* = 13.0 y 9.4 Hz), 2.80 (ddd, 1H, *J* = 16.1, 8.7 y 2.7 Hz), 3.10 (dd, 1H, *J* = 16.0 y 7.5 Hz), 3.12 (dd, 1H, *J* = 10.0 y 7.5 Hz), 3.65 (tdd, 1H, *J* = 9.3, 8.2 y 4.8 Hz), 4.44 (d, 1H, *J* = 10.7 Hz), 4.51 (d, 1H, *J* = 10.7 Hz), 7.02--7.05 (m, 2H), and 7.05--7.30 (m,12 H); ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 27.3, 30.8, 34.2, 39.0, 41.3, 68.1, 77.6, 79.0, 124.5, 125.4, 126.1, 126.1, 127.7, 128.3, 128.43, 128.7, 129.4, 137.7, 140.2, and 145.6. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~26~H~27~NONa, 392.1985; found, 392.1971. *cis*-**19b**: Yellow oil ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.58--1.65 (m, 1H), 1.70--1.84 (m, 3H), 2.00--2.16 (m, 1H), 2.70 (dd, 1H, *J* = 13.0 y 6.0 Hz), 2.65--2.77 (m, 1H), 2.86 (ddd, 1H, *J* = 15.6, 8.8, 5.2 Hz), 3.02 (ddd, 1H, *J* = 15.6, 8.8, 6.0 Hz), 3.20 (1H, dd, *J* = 13.0 y 4.0 Hz), 3.31--3.41 (m, 1H), 4.04 (d, 1H, *J* = 10.2 Hz), 4.43 (d, 1H, *J* = 10.2 Hz), 6.94--6.98 (2H, m), 7.20--7.30 (m, 11H), and 7.51--7.54 (m, 1H). ^13^C NMR (DMSO-*d*~6~, 100 MHz): δ (ppm) 24.2, 29.8, 29.9, 33.5, 40.3, 64.8, 76.7 (C), 77.0, 123.6, 124.2, 125.8, 126.2, 127.5, 127.9, 128.1, 128.4, 128.9, 136.9, 139.3, 144.0, and 145.7. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~26~H~27~NONa, 392.1985; found, 392.1967.

### *O*-Benzyl-*N*-(1-(4-methylpent-3-en-1-yl)-2,3-dihydro-1*H*-inden-1-yl)hydroxylamine (**23c**) {#sec4.2.3}

Method (A). Yellow oil (57.8 mg, 50%). Compound **23c** was prepared according to the general procedure from oxime ether **18b** (136.0 mg, 0.36 mmol), tributyltin hydride (100.0 μL, 0.37 mmol), AIBN (17.0 mg, 0.10 mmol), and cyclohexane (14.0 mL) during 6 h. The crude product was purified by column chromatography, silica gel 60--200 mesh (15--25% DCM, 5% gradient). ^1^H NMR (CDCl~3~, 300 MHz): δ (ppm) 1.54 (s, 3H), 1.66 (s, 3H), 1.72--1.81 (m, 1H), 1.86--2.05 (m, 3H), 2.08--2.22 (m, 2H), 2.79--2.89 (m, 1H), 2.94--3.04 (m, 1H), 4.56 (d, 2H, *J* = 11.4 Hz), 4.61 (d, 2H, *J* = 11.4 Hz), 5.07--5.12 (m, 2H), 5.54 (s, 1H), and 7.15--7.34 (m, 9H). ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 17.9, 23.3, 25.9, 30.4, 34.7, 36.8, 72.7, 77.2, 124.5, 124.6, 124.8, 126.3, 127.8, 127.9, 128.4, 128.5, 131.7, 138.3, 144.4, and 145.5. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~22~H~27~NONa, 344.1990; found, 344.1975.

### *trans*-1′-(Benzyloxy)-5′-(4-chlorophenylmethyl)-2,3-dihydrospiro\[indene-1,2′-pyrrolidine\](**19d**) {#sec4.2.4}

Method (A). Yellow oil *trans* diastereomer (16.8 mg, 20%). Compound **19d** was prepared according to the general procedure from oxime ether **18f** (124.0 mg, 0.23 mmol), tributyltin hydride (0.08 mL, 0.28 mmol), AIBN (9.6 mg, 0.06 mmol), and cyclohexane (10.6 mL) during 3 h. The crude product was purified by preparative plate chromatography (silica gel, 1000 μm, 10 cm × 20 cm) with two elutions with 5% ethyl acetate/hexane. Method (B). Yellow oil *trans* diastereomer (26.0 mg, 23%). Compound **19d** was prepared according to the general procedure from oxime ether **18f** (150.0 mg, 0.23 mmol), tributyltin hydride (0.09 mL, 0.34 mmol), Et~3~B (0.70 mL, 0.70 mmol), and cyclohexane (14.0 mL). The crude product was purified by preparative plate chromatography (silica gel, 1000 μm, 10 cm × 20 cm) with two elutions with 5% ethyl acetate/hexane. ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.59--1.69 (m, 2H), 1.91--2.19 (m, 4H), 2.47 (ddd, 1H, *J* = 13.2, 7.8, 2.6 Hz), 2.67 (dd, 1H, *J* = 13.1, 9.2 Hz), 2.84 (ddd, 1H, *J* = 15.7, 8.6, 2.6 Hz), 3.06--3.18 (m, 2H), 3.60--3.68 (m, 1H), 4.45 (d, 1H, *J* = 10.8 Hz), 4.51 (d, 1H, *J* = 10.7 Hz), 7.06 (dd, 2H, *J* = 7.0, 2.6 Hz), 7.16 (d, 2H, *J* = 8.1 Hz), and 7.22--7.30 (m, 8H); ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 27.0, 30.5, 33.9, 38.7, 40.3, 67.7, 78.8, 124.3, 125.2, 125.9, 127.6, 128.1, 128.3, 128.5, 130.5, 131.2, 137.4, 138.4, 144.9, and 145.4. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ calcd for C~26~H~27~NOCl, 404.1781; found, 404.1781.

### *trans*-5′-Benzhydryl-1′-(benzyloxy)-2,3-dihydrospiro\[indene-1,2′-pyrrolidine\] (**19e**) {#sec4.2.5}

Yellow oil *trans* diastereomer (40.6 g, 57%). Method (A). Compound **19e** was prepared according to the general procedure from oxime ether **18g** (94.0 mg, 0.16 mmol), tributyltin hydride (54.0 μL, 0.20 mmol), AIBN (7.0 mg, 0.04 mmol), and cyclohexane (8.0 mL). The crude product was purified by preparative plate chromatography (silica gel, 1000 μm, 10 cm × 20 cm) with two elutions with 5% diethyl ether/hexane. Method (B). Yellow oil *trans* diastereomer (53.5 g, 50%). Compound **19e** was prepared according to the general procedure from oxime ether **18g** (141.0 mg, 0.24 mmol), tributyltin hydride (0.08 mL, 0.29 mmol), Et~3~B (0.60 mL, 0.60 mmol), and cyclohexane (12.0 mL). The crude product was purified by preparative plate chromatography (silica gel, 1000 μm, 10 cm × 20 cm) with two elutions with 5% diethyl ether/hexane. ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.74--1.79 (m, 2H), 1.85--1.92 (m, 1H), 1.98--2.11 (m, 2H), 2.80--2.95 (m, 2H), 3.01--3.08 (m, 1H), 3.74 (s, 2H), 4.12--4.18 (m, 1H), 4.38 (s, 1H), 6.62--6.63 (m, 2H), and 7.15--7.55 (m, 17H); ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 25.7, 30.8, 34.9, 56.3, 67.3, 76.6, 79.0, 124.6, 126.2, 126.4, 127.5, 127.9, 128.2, 128.4, 128.9, 129.0, 137.1, 143.9, 145.0, and 145.8. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ calcd for C~32~H~32~NO, 446.2484; found, 466.2484.

### *trans*/*cis*-2-(1′-(Benzyloxy)-2,3-dihydrospiro\[indene-1,2′-pyrrolidin\]-5′-yl)acetonitrile (**9**) {#sec4.2.6}

Method (A). Yellow oil (48.9 mg, 66%). Diastereomers: *cis* 15.3 mg (21%), *trans* 33.6 mg (45%). Compound **9** was prepared according to the general procedure from oxime ether **8** (104.5 mg, 0.23 mmol), tributyltin hydride (0.08 mL, 0.28 mmol), AIBN (14 mg, 0.09 mmol), and cyclohexane (11.5 mL). The crude product was purified by flash column chromatography, silica gel 230--400 mesh (60--95% benzene/hexane, 5% gradient). Method (B). Yellow oil (51.2 mg, 64%). Diastereomers: *cis* 11.2 mg (14%), *trans* 40.0 mg (50%). Compound **9** was prepared according to the general procedure from oxime ether **8** (112.3 mg, 0.25 mmol), tributyltin hydride (0.08 mL, 0.30 mmol), Et~3~B (0.70 mL, 0.70 mmol), and cyclohexane (13.0 mL). The crude product was purified by flash column chromatography, silica gel 230--400 mesh (60--95% benzene/hexane, 5% gradient). *trans*-**9**: mp 74--75 °C; white solid; ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.76--1.85 (m, 1H), 2.09--2.30 (m, 4H), 2.37 (dd, 1H, *J* = 7.0 Hz), 2.46--2.52 (m, 2H), 2.86 (ddd, 1H, *J* = 16.6, 2.0 Hz), 3.11 (dt, 1H, *J* = 16.0, 8.0 Hz), 3.58--3.65 (m, 1H), 4.55 (dd, 2H, *J* = 11.0, 3.0 Hz), 7.11--7.12 (m, 2H), and 7.22--7.31 (m, 6H); ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 22.1, 26.2, 30.4, 33.9, 38.4, 61.4, 77.6, 78.5, 118.2, 124.5, 124.8, 126.1, 127.9, 128.3, 128.7, 137.1, 144.2, and 145.2. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ calcd for C~21~H~23~N~2~O, 319.1810; found, 319.1813. *cis*-**9**: yellow oil; ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.73--1.95 (m, 3H), 2.11--2.28 (m, 2H), 2.48 (ddd, 2H, *J* = 17.6, 4.0 Hz), 2.70--2.76 (m, 1H), 2.89--2.97 (m, 1H), 3.03--3.11 (m, 1H), 3.31--3.35 (m, 1H), 4.10 (d, 1H, *J* = 11.0 Hz), 4.32 (d, 1H, *J* = 11.0 Hz), 7.04--7.05 (m, 2H), 7.27--7.38 (m, 6H), and 7.57--7.59 (m, 1H); ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 22.6, 24.6, 30.2, 30.5, 34.4, 59.9, 77.5, 77.9, 118.1, 124.1, 124.6, 126.6, 128.0, 128.1, 128.2, 129.0, 137.4, 144.5, and 145.1. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ calcd for C~21~H~23~N~2~O, 319.1810; found, 319.1813.

General Procedure for the Synthesis of Spirocycles **25** {#sec4.3}
---------------------------------------------------------

Conditions described earlier as Methods (A) and (B) were also used for this case. But after removal of cyclohexane, dehydrostannylation was carried out; ∼14 mL of dichloromethane, ∼2.5 g of silica gel 70--230 mesh, and ∼5 drops of acetic acid were added, the mixture was stirred for 12 h, filtered, washed with chloroform, and finally concentrated under reduced pressure. Finally, the solvent was removed and the crude product filtered on a short column charged with a silica gel 70--230 mesh and eluted initially with hexane, then with a solution of toluene/hexane (15%) to remove organotin impurities. After evaporation of the solvent, this crude prepurified was passed over flash column chromatography filled with a silica gel 230--400 mesh to obtain the corresponding spirocyclic compounds **25**.

### *trans*/*cis*-2-Benzyl-1-(benzyloxy)-6-methylene-1-azaspiro\[4.4\]nonane (**25i**) {#sec4.3.1}

Method (A) (62.2 mg, 67%). Diastereomers: *cis* 29.0 mg (31%), *trans* 33.2 mg (36%). Compound **25i** was prepared according to the general procedure from oxime ether **18i** (100.0 mg, 0.30 mmol), tributyltin hydride (100.0 μL, 0.36 mmol), AIBN (12.6 mg, 0.08 mmol), and cyclohexane (15.0 mL). The crude product was purified by flash column chromatography, silica gel 230--400 mesh (1--3.5% ethyl acetate/hexanes, 0.5% gradient). Method (B) (61.6 mg, 45%). Diastereomers: *cis* 21.6 mg (15%), *trans* 40.0 mg (30%). Compound **25i** was prepared according to the general procedure from oxime ether **18i** (150.0 mg, 0.45 mmol), tributyltin hydride (150.0 μL, 0.54 mmol), Et~3~B (1.1 mL, 1.1 mmol), and cyclohexane (22.5 mL). The crude product was purified by flash column chromatography, silica gel 230--400 mesh (1--3.5% ethyl acetate/hexanes, 0.5% gradient). *trans*-**25i**: yellow oil ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.45--1.90 (m, 7H), 2.16--2.21 (m, 1H), 2.30--2.36 (m, 1H), 2.53--2.65 (m, 2H), 3.15--3.19 (dd, 1H), 3.51--3.59 (m, 1H), 4.68 (d, 1H, *J* = 10.5 Hz), 4.73 (d, 1H, *J* = 10.5 Hz), 4.82 (s, 1H), 5.00 (s, 1H), and 7.13--7.28 (m, 10H); ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 22.3, 26.4, 32.6, 33.9, 38.6, 40.3, 66.6, 76.7, 77.8, 108.1, 125.9, 126.1, 127.9, 128.0, 128.3, 128.4, 128.6, 128.7, 129.2, 129.3, 137.6, 140.1, and 155.5. HRMS (ESI) calcd for \[C~23~H~27~NO + H\]^+^, 334.2171; found, 334.2168. *cis*-**25i**: yellow oil ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm), 1.34--1.60 (m, 6H), 1.66--1.76 (m, 1H), 1.79--1.96 (m, 1H), 2.17--2.33 (m, 3H), 2.56--2.62 (m, 1H), 3.11--3.17 (m, 1H), 4.68 (d, 1H, *J* = 10.5 Hz), 4.78 (d, 1H, *J* = 10.5 Hz), 5.01 (s, 1H), 5.31 (s, 1H), and 7.08--7.30 (m, 10H); ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 22.9, 24.9, 30.0, 33.2, 36.4, 41.2, 66.1, 75.1, 77.8, 106.7, 125.9, 126.2, 127.4, 127.7, 127.9, 128.0, 128.3, 128.3, 128.7, 129.3, 137.9, 139.9, and 156.2. HRMS (ESI-TOF) *m*/*z*: calcd for \[M + H\]^+^ C~23~H~28~NO, 334.2171; found, 334.2161.

### *trans*-2-Benzhydryl-1-(benzyloxy)-6-methylene-1-azaspiro\[4.4\]nonane (**25j**) {#sec4.3.2}

Method (A). Yellow oil, only *trans* diastereomer (52.2 mg, 58%). Compound **25j** was prepared according to the general procedure from oxime ether **18j** (89.0 mg, 0.22 mmol), tributyltin hydride (67.0 μL, 0.24 mmol), AIBN (10.0 mg, 0.06 mmol), and cyclohexane (11.0 mL). The crude product was purified by flash column chromatography, silica gel 230--400 mesh (5--15% ethyl acetate/hexanes, 5% gradient). Method (B). Yellow oil *trans* diastereomer (48.2 mg, 58%). Compound **25j** was prepared according to the general procedure from oxime ether **18j** (100.0 mg, 0.24 mmol), tributyltin hydride (81.6 μL, 0.29 mmol), Et~3~B (0.60 mL, 0.60 mmol), and cyclohexane (12.0 mL). The crude product was purified by flash column chromatography, silica gel 230--400 mesh (5--15% ethyl acetate/hexanes, 5% gradient). ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.36--1.54 (m, 5H), 1.66--1.77 (m, 2H), 2.20--2.32 (m, 3H), 3.84--3.87 (m, 1H), 3.99 (d, 1H, *J* = 10.15), 4.22 (d, 1H, *J* = 7.41), 4.43 (d, 1H, *J* = 9.76 Hz), 4.99 (s, 1H), 5.26 (s, 1H); 6.90--6.92 (m, 2H), and 7.05--7.33 (m, 12H); ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 23.1, 25.6, 33.3, 36.4, 56.0, 67.9, 76.3, 76.4, 107.2, 126.1, 126.1, 127.5, 128.0, 128.1, 128.3, 128.7, 129.0, 137.8, 143.8, and 144.0. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ calcd for C~29~H~32~NO, 410.2484; found, 410.2483.

General Procedure for Synthesis of Oxime Ethers **8** and **18a--j** {#sec4.4}
--------------------------------------------------------------------

To a solution of compounds **17a--k** (1.00 equiv) in chloroform or methanol (0.22 M) were added *O*-benzylhydroxylamine hydrochloride (1.30 equiv) and dry pyridine (2.50 equiv). The resulting mixture was refluxed at 70 °C under an argon atmosphere for 14 h. The reaction mixture was quenched with saturated NaHCO~3~ solution, extracted with ethyl acetate, and the organic layer was dried over anhydrous magnesium sulphate. The solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel.

### *E*/*Z*-Ethyl 6-((Benzyloxy)imino)-8-(2-bromophenyl)oct-2-enoate (**18a**) {#sec4.4.1}

Yellow oil (155 mg, 73%). Compound **18a** was prepared according to the general procedure from ketone **17a** (161 mg, 0.48 mmol), *O*-benzylhydroxylamine hydrochloride (102 mg, 0.64 mmol), pyridine (0.11 mL, 1.36 mmol), and methanol anhydrous (2 mL). The crude product was purified by column chromatography silica gel 60--200 mesh (50% methylene chloride/hexane). ^1^H NMR (CDCl~3~, 400 MHz) *E*,*Z* isomers: δ (ppm) 1.27 (t, 3H, *J* = 7.2 Hz), 1.28 (t, 3H, *J* = 7.2 Hz), 2.20--2.25 (m, 1H), 2.34--2.51 (m, 11H), 2.89--2.95 (m, 4H), 4.17 (q, 2H, *J* = 7.2 Hz), 4.18 (q, 2H, *J* = 7.2 Hz), 5.05 (s, 2H), 5.08 (s, 2H), 5.79 (d, 1H, *J* = 15.6 Hz), 5.80 (d, 1H, *J* = 15.6 Hz), 6.87--7.09 (m, 2H), 7.17--7.18 (m, 2H), 7.29--7.36 (m, 14H), 7.49 (d, 1H, *J* = 7.6 Hz), and 7.51 (d, 1H, *J* = 7.6 Hz). ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 14.8, 27.7, 28.8, 29.0, 29.6, 32.6, 33.5, 34.8, 60.7, 75.7, 76.1, 122.4, 128.0, 128.1, 128.3, 128.5, 128.6, 131.0, 133.3, 133.3, 138.6, 140.9, 147.8, 148.2, 159.0, and 166.8. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~23~H~26~BrNO~3~Na, 446.0988; found, 466.0973.

### *E*/*Z*-1-(2-Bromophenyl)-7-phenylhept-6-en-3-one *O*-Benzyl Oxime (**18b**) {#sec4.4.2}

Yellow oil (441 mg, 67%). Compound **18b** was prepared according to the general procedure from ketone **17b** (500 mg, 1.46 mmol), *O*-benzylhydroxylamine hydrochloride (481 mg, 1.90 mmol), pyridine (0.3 mL, 3.86 mmol), and methanol anhydrous (6 mL). The crude product was purified by column chromatography, silica gel 60--200 mesh (30% methylene chloride/hexanes). ^1^H NMR (CDCl~3~, 400 MHz) *E*,*Z* isomers: δ (ppm) 2.26--2.65 (m, 12H), 2.92--2.98 (m, 4H), 5.09 (s, 2H), 5.10 (s, 2H), 6.11--6.21 (m, 2H), 6.32--6.40 (m, 2H), 7.00--7.36 (m, 26H), and 7.50 (d, 2H, *J* = 7.2 Hz). ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 28.7, 29.1, 29.4, 29.8, 32.3, 33.2, 34.6, 34.6, 75.7, 124.4, 124.5, 126.2, 127.2, 127.2, 127.7, 127.7, 127.8, 128.0, 128.1, 128.2, 128.5, 128.6, 129.5, 129.6, 130.6, 130.7, 132.9, 137.6, 137.7, 138.5, 140.7, 140.8, and 159.7. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~26~H~26~BrNONa, 470.1090; found, 470.1075.

### *E*/*Z*-1-(2-Bromophenyl)-7-methyloct-6-en-3-one *O*-Benzyl Oxime (**18c**) {#sec4.4.3}

Yellow oil (407 mg, 75%). Compound **18c** was prepared according to the general procedure from ketone **17c** (400 mg, 1.63 mmol), *O*-benzylhydroxylamine hydrochloride (261 mg, 1.63 mmol), pyridine (0.3 mL, 3.86 mmol), and methanol anhydrous (6 mL). The crude product was purified by column chromatography, silica gel 60--200 mesh (20% DCM/hexanes). ^1^H NMR (CDCl~3~, 400 MHz) *E*,*Z* isomers: δ (ppm) 1.57 (s, 3H), 1.60 (s, 3H), 1.67 (s, 6H), 2.12--2.24 (m, 6H), 2.36--2.41 (m, 2H), 2.44--2.50 (m, 2H), 2.58--2.64 (m, 2H), 2.91--2.98 (m, 4H), 5.03--5.10 (m, 2H), 5.100 (s, 2H), 5.103 (s, 2H), 7.00 (m, 2H), 7.11--7.20 (m, 4H), 7.29--7.38 (m, 10H), and 7.49--7.53 (m, 2H). ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 17.8, 18.0, 24.6, 25.2, 25.9, 29.0, 32.4, 33.3, 34.8, 34.8, 75.6, 123.4, 123.5, 124.4, 124.5, 127.7, 127.7, 127.9, 128.0, 128.1, 128.2, 128.4, 130.6, 130.7, 132.4, 132.7, 132.9, 138.6, 140.8, 141.0, and 160.4. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ calcd for C~22~H~27~BrNO, 400.1271; found, 400.1275.

### *E*/*Z*-Ethyl-6-((benzyloxy)imino)-8-(2-iodophenyl)oct-2-enoate (**18d**) {#sec4.4.4}

Yellow oil (200.8 mg, 73%). Compound **18d** was prepared according to the general procedure from ketone **17d** (220.0 mg, 0.56 mmol), *O*-benzylhydroxylamine hydrochloride (135.4 mg, 0.84 mmol), dry pyridine (112.8 μL), and chloroform (2.5 mL). The crude product was purified by column chromatography (silica gel 70--230 mesh, 8--10% ethyl acetate/hexanes, 1% gradient). ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 1.18--1.23 (m, 6H), 2.16--2.19 (m, 2H), 2.30--2.38 (m, 6H), 2.41--2.51 (m, 4H), 2.80--2.86 (m, 4H), 4.07--4.13 (m, 4H), 5.01 (s, 4H), 5.71--5.76 (m, 2H), 6.77--6.90 (m, 4H), 7.01 (dd, 1H, *J*~1~ = 7.6, *J*~2~ = 1.6), 7.10--7.17 (m, 2H), 7.20--7.32 (m, 2H), and 7.69--7.73 (m, 2H). ^13^C RMN (100 MHz, CDCl~3~): δ (ppm) 14.3, 27.3, 28.4, 28.6, 29.4, 34.7, 36.6, 60.2, 60.3, 75.7, 75.7, 100.1, 100.3 (C--I), 121.9, 122.0, 127.7, 128.0, 128.1, 128.3, 128.5, 128.5, 129.6, 129.6, 138.1, 138.2, 139.5, 139.5, 143.6, 143.8, 147.5, 147.8, 158.4, 158.6, 166.4, and 166.6. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~23~H~26~INO~3~Na, 514.0855; found, 514.0854.

### *E*/*Z*-1-(2-Iodophenyl)-7-phenylhept-6-en-3-one *O*-Benzyl Oxime (**18e**) {#sec4.4.5}

Yellow oil (242.6 mg, 88%). Compound **18e** was prepared according to the general procedure from ketone **17e** (220.0 mg, 0.56 mmol), *O*-benzylhydroxylamine hydrochloride (135.4 mg, 0.84 mmol), dry pyridine (112.8 μL), and chloroform (2.5 mL). The crude product was purified by column chromatography (silica gel 70--230 mesh, 8--10% ethyl acetate/hexanes, 1% gradient). ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 2.21--2.25 (m, 3H), 2.33--2.55 (m, 9H), 2.83--2.89 (m, 4H), 5.03 (s, 4H), 6.07 (m, 2H), 6.27--6.34 (m, 2H), 6.77--6.82 (m, 2H), 7.05 (dd, 1H, *J*~1~ = 7.5 Hz, *J*~2~ = 1.7), 7.10--7.16 (m, 4H), 7.18--7.32 (m, 21H), and 7.78--7.73 (m, 2H). ^13^C RMN (100 MHz, CDCl~3~): δ (ppm) 28.6, 29.2, 29.3, 29.7, 34.4, 34.9, 36.7, 37.7, 75.5, 100.2, 100.4, 126.0, 126.1, 127.0, 127.0, 127.6, 127.6, 127.8, 127.9, 128.0, 128.0, 128.1, 128.1, 128.3, 128.4, 128.5, 129.4, 129.5, 129.6, 129.6, 130.6, 130.6, 137.5, 137.6, 138.3, 139.5, 143.9, 144.0, 159.4, and 159.5. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~26~H~16~INONa, 518.0957; found, 518.0960.

### *E*/*Z*-7-(4-Chlorophenyl)-1-(2-iodophenyl)hept-6-en-3-one *O*-Benzyl Oxime (**18f**) {#sec4.4.6}

Yellow oil (448 mg, 87%). Compound **18f** was prepared according to the general procedure from ketone **17f** (415 mg, 0.976 mmol), *O*-benzylhydroxylamine hydrochloride (203 mg, 1.27 mmol), pyridine (0.19 mL, 2.42 mmol), and chloroform (4.4 mL). The crude product was purified by column chromatography, silica gel 70--230 mesh (5% diethyl ether/hexane). ^1^H NMR (CDCl~3~, 400 MHz) *E*,*Z* isomers: δ (ppm) 2.35 (t, 2H, *J* = 7.4 Hz), 2.42--2.72 (m, 10H), 2.98 (dt, 4H, *J* = 8.9, 8.1, 5.3 Hz), 5.15 (s, 4H), 6.19 (dt, 2H, *J* = 15.8, 6.7 Hz), 6.37 (dd, 2H, *J* = 15.7, 13.1 Hz), 6.92 (t, 2H, *J* = 7.6 Hz), 7.13--7.51 (m, 22H), and 7.84 (d, 2H, *J* = 7.9 Hz). ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 28.4, 29.2, 29.6, 34.2, 34.8, 36.7, 37.6, 75.5, 100.1, 100.3, 127.2, 127.2, 127.6, 127.9, 128.0, 128.1, 128.3, 128.4, 128.5, 128.6, 129.4, 129.4, 129.5, 129.6, 130.1, 130.2, 132.5, 132.5, 136.0, 136.1, 138.3, 138.3, 139.4, 143.8, 143.9, 159.2, and 159.3. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ calcd for C~26~H~26~ClINO, 530.0748; found, 530.0746.

### *E*/*Z*-1-(2-Iodophenyl)-7,7-diphenylhept-6-en-3-one *O*-Benzyl Oxime (**18g**) {#sec4.4.7}

Yellow oil (130.9 mg, 71%). Compound **18g** was prepared according to the general procedure from ketone **17g** (153.0 mg, 0.32 mmol), *O*-benzylhydroxylamine hydrochloride (77.4 mg, 0.48 mmol), pyridine (0.1 mL, 1.34 mmol), and chloroform (1.5 mL). The crude product was purified by column chromatography, silica gel 70--230 mesh (7--9% diethyl ether/hexane, 2% gradient). ^1^H RMN (400 MHz, CDCl~3~): δ (ppm) 1.79 (d, 2H, *J* = 7.02 Hz), 2.15 (t, 2H, *J* = 7.41 Hz), 2.24--2.29 (m, 4H), 2.37--2.43 (m, 2H), 2.72--2.79 (m, 4H), 4.96 (s, 2H), 4.99 (s, 2H), 5.93--5.98 (m, 2H), 6.71--6.76 (m, 2H), 6.92 (d, 1H, *J* = 7.61 Hz), 7.01--7.28 (m, 33H), and 7.65 (t, 2H, *J* = 7.51 Hz). ^13^C RMN (100 MHz, CDCl~3~): δ (ppm) 26.3, 26.8, 28.9, 29.2, 34.8, 36.8, 37.8, 75.6, 75.6, 100.3, 100.5, 127.0, 127.1, 127.1, 127.4, 127.7, 127.7, 127.7, 128.0, 128.0, 128.1, 128.1, 128.1, 128.2, 128.2, 128.3, 128.5, 128.5, 129.6, 129.7, 130.0, 138.4, 138.4, 139.5, 139.5, 140.0, 140.1, 142.4, 142.6, 142.6, 144.0, 144.0, 159.5, and 159.5. HRMS (ESI-TOF) *m*/*z*: \[M + K\]^+^ calcd for C~32~H~30~INOK, 610.1009; found, 610.1008.

### *E*/*Z*-1-(2-Iodophenyl)-7-(4-nitrophenyl)hept-6-en-3-one *O*-Benzyl Oxime (**18h**) {#sec4.4.8}

Yellow oil (128 mg, 65%). Compound **18h** was prepared according to the general procedure from ketone **17h** (159.0 mg, 0.37 mmol), *O*-benzylhydroxylamine hydrochloride (100.0 mg, 0.63 mmol), pyridine (0.07 mL, 0.92 mmol), and mixture of DCM and methanol (1 mL methanol and 0.6 mL dichloromethane). The crude product was purified by column chromatography, silica gel 70--230 mesh (10--14% ethyl acetate/hexane, 2% gradient). ^1^H NMR (CDCl~3~, 400 MHz) *E*,*Z* isomers: δ (ppm) 2.31 (t, 2H, *J* = 7.3 Hz), 2.43--2.61 (m, 10H), 2.90--2.95 (m, 4H), 5.06 (d, 1H, *J* = 7.0 Hz), 5.09 (s, 3H), 6.32--6.44 (m, 4H), 6.86 (t, 2H, *J* = 7.1 Hz), 7.10--7.21 (m, 4H), 7.28--7.37 (m, 17H), 7.78 (d, 2H, *J* = 7.8 Hz), and 8.12 (dd, 4H, *J* = 8.8, 3.4 Hz). ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 28.1, 29.3, 29.4, 29.6, 33.9, 34.8, 36.7, 37.6, 63.5, 75.6, 75.6, 100.1, 100.3, 123.9, 126.5, 127.6, 127.7, 127.8, 128.0, 128.1, 128.3, 128.4, 128.5, 128.8, 129.5, 129.6, 134.7, 134.9, 138.2, 138.3, 143.7, 143.8, 144.0, 144.1, and 158.8. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~26~H~25~IN~2~ONa, 563.0808; found, 563.0811.

### *E*/*Z*-1-Phenyldec-1-en-9-yn-5-one *O*-Benzyl Oxime (**18i**) {#sec4.4.9}

Yellow oil (207.2 mg, 95%). Compound **18i** was prepared according to the general procedure from ketone **17i** (150.0 mg, 0.66 mmol), *O*-benzylhydroxylamine hydrochloride (159.6 mg, 0.99 mmol), pyridine (140.0 μL), and chloroform (2.8 mL). The crude product was purified by column chromatography, silica gel 70--230 mesh (7--10% % diethyl ether/hexanes, 1% gradient). RMN ^1^H (400 MHz, CDCl~3~): δ (ppm) 1.78--1.83 (m, 2H), 1.93--1.94 (t, 1H, *J* = 2.4 Hz), 1.99--2.01 (t, 1H, *J* = 2.4 Hz), 2.24--2.27 (m, 2H), 2.34--2.56 (m, 5H), 5.12 (s, 2H), 6.21--6.26 (m, 1H), 6.40--6.47 (m, 1H), and 7.25--7.39 (m, 10H). RMN^13^C (100 MHz, CDCl~3~): δ (ppm) 18.1, 18.7, 24.8, 25.2, 27.8, 28.5, 29.3, 29.9, 33.3, 34.2, 68.8, 68.9, 75.5, 75.5, 83.8, 84.0, 126.1, 127.0, 127.1, 127.6, 127.6, 127.9, 128.0, 128.3, 128.5, 129.4, 130.6, 130.6, 137.6, 138.4, 159.8, and 159.8. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ calcd for C~23~H~26~NO, 332.2014; found, 332.2011.

### *E*/*Z*-1,1-Diphenyldec-1-en-9-yn-5-one *O*-Benzyl Oxime (**18j**) {#sec4.4.10}

Yellow oil (98.5 mg, 62%). Compound **18j** was prepared according to the general procedure from ketone **17j** (123.0 mg, 0.39 mmol), *O*-benzylhydroxylamine hydrochloride (93.4 mg, 0.58 mmol), pyridine (117.0 μL) and chloroform (1.8 mL). The crude product was purified by flash column chromatography, silica gel 230--400 mesh (7--10% % diethyl ether/hexanes, 1% gradient). RMN ^1^H (400 MHz, CDCl~3~): δ (ppm) 1.69--1.79 (m, 4H), 1.97--2.00 (m, 2H), 2.19--2.24 (m, 3H), 2.26--2.29 (m, 2H), 2.37--2.44 (m, 7H), 2.51--2.55 (m, 2H), 5.10 (s, 2H), 5.14 (s, 2H), 6.12--6.16 (m, 2H), and 7.23--7.46 (m, 30H). RMN ^13^C (100 MHz, CDCl~3~): δ (ppm) 18.1, 18.6, 24.8, 25.1, 26.2, 26.7, 27.6, 28.7, 33.2, 34.4, 68.9, 69.0, 75.5, 75.5, 127.0, 127.0, 127.1, 127.1, 127.3, 127.3, 127.6, 128.0, 128.1, 128.2, 128.3, 128.3, 128.3, 129.9, 138.3, 138.4, 139.9, 140.1, 142.5, 142.6, 159.7, and 159.9. HRMS (ESI-TOF) *m*/*z*: \[M + K\]^+^ calcd for C~29~H~29~NOK, 446.1886; found, 446.1888.

### *E*/*Z*-6-((Benzyloxy)imino)-8-(2-iodophenyl)oct-2-enenitrile (**8**) {#sec4.4.11}

Yellow oil (147.2 mg, 74%). Compound **8** was prepared according to the general procedure from **17k** (153 mg, 0.45 mmol), *O*-benzylhydroxylamine hydrochloride (86 mg, 0.54 mmol), pyridine (0.09 mL, 1.12 mmol), and methanol (2 mL). The crude product was purified by column chromatography, silica gel 70--230 mesh (17% ethyl acetate/hexane, 3% gradient). ^1^H NMR (CDCl~3~, 400 MHz) *E*,*Z* isomers: δ (ppm), 2.22 (dt, 5H, *J* = 7.0 Hz), 2.38--2.66 (m, 19H), 2.87--2.96 (m, 8H), 5.08 (s, 4H), 5.09 (s, 4H), 5.21--5.25 (m, 4H), 6.34--6.42 (m, 2H), 6.57--6.66 (m, 2H), 6.86--6.90 (m, 4H), 7.07 (dd, 3H, *J* = 7.0 Hz), 7.17--7.25 (m, 6H), 7.29--7.37 (m, 19H), and 7.79 (dd, 4H, *J* = 7.0 Hz). ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 26.8, 27.1, 27.9, 28.2, 29.1, 29.3, 29.4, 29.4, 32.6, 33.0, 34.6, 34.6, 36.5, 36.5, 37.5, 37.5, 75.7, 75.8, 75.8, 99.9, 100.0, 100.1, 100.1, 100.2, 100.4, 100.4, 117.4, 127.7, 127.8, 127.8, 127.9, 128.0, 128.1, 128.2, 128.2, 128.3, 128.3, 128.3, 128.4, 128.4, 128.5, 128.5, 128.5, 128.8, 129.6, 129.6, 129.7, 130.9, 137.8, 137.9, 138.1, 138.2, 139.5, 139.5, 143.3, 143.5, 143.5, 143.6, 153.2, 153.9, 154.1, 154.6, 157.5, 157.6, 157.7, and 157.7 HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ calcd for C~21~H~22~IN~2~O, 400.1271; found, 400.1275.

General Procedure for Synthesis of Ketones **17a--k** {#sec4.5}
-----------------------------------------------------

### Methodology A {#sec4.5.1}

A microwave tube was charged with β-ketoester **16d--j** (1.00 mmol), LiCl (4.00 mmol), silica gel (70--230 mesh, Merck, 0.40 g per 1.00 mmol of substrate), DMF (25--75 μL), and DCM (3 mL). The mixture was homogenized by stirring and the excess of DCM removed under vacuum. The tube was sealed with its plastic cup and heated in a CEM Discover Microwave reactor (using the dynamic method) until the substrate was consumed (monitored by TLC). The silica gel-supported reaction mixture was cooled to room temperature and poured into a chromatographic column partially filled with silica gel. Then, the product was isolated using a gradient of ethyl ether or ethyl acetate or dichloromethane/hexane mixture.^[@ref14]^

### Methodology B {#sec4.5.2}

To a solution of compounds β-ketoester **16a--c** (1.00 equiv) in DMSO (1.2 M) were added LiCl (2.00 equiv) and H~2~O (1.00 equiv). The reaction mixture was quenched with brine and extracted with ethyl acetate; the organic layer was dried over MgSO~4~. The solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel.^[@ref13]^

### Methodology C {#sec4.5.3}

A microwave tube was charged with β-ketoester **16k** (1.00 equiv), LiCl (4.40 equiv), H~2~O (1.5 equiv), and DMF (0.98 M). The tube was sealed with its plastic cup and heated with stirring in a CEM Discover Microwave reactor (using the dynamic method) until the substrate was consumed (monitored by TLC). The mixture reaction was washed with water and extracted with diethyl ether; the organic layer was dried over Na~2~SO~4~. The solvent was removed, and the product was isolated using gradient of ethyl acetate/hexane mixture.^[@ref15]^

### Ethyl (E)-8-(2-Bromophenyl)-6-oxooct-2-enoate (**17a**) {#sec4.5.4}

Yellow oil, (171.1 mg, 46%), Compound **17a** was prepared according to the procedure for Methodology B from methyl (*E*)-2-(2-bromobenzyl)-3-oxo-7-phenylhept-6-enoate (**16a**) (440 mg, 1.10 mmol), LiCl (94 mg, 2.20 mmol), and H~2~O (20 mg, 1.11 mmol) in 3 mL of DMSO. The mixture was refluxed at 110 °C for 5 h. The crude product was purified by column chromatography, silica gel 70--200 mesh (30% DCM/hexane). ^1^H NMR (CDCl~3~, 300 MHz): δ (ppm) 1.28 (t, 3H, *J* = 7.2 Hz), 2.43--2.50 (m, 2H), 2.54--2.59 (m, 2H), 2.75 (t, 2H, *J* = 7.6 Hz), 3.01 (t, 2H, *J* = 7.6 Hz), 4.17 (q, 2H, *J* = 7.2 Hz), 5.80 (d, 1H, *J* = 15.2 Hz), 6.90 (dt, 1H, *J* = 15.6, 6.4 Hz), 7.03--7.09 (m, 1H), 7.21--7.23 (m, 2H), and 7.51 (d, 1H, *J* = 7.8 Hz). ^13^C NMR (CDCl~3~, 75 MHz): δ (ppm) 14.4, 26.1, 30.4, 40.8, 42.5, 60.3, 122.2, 124.3, 127.7, 128.1, 130.7, 133.0, 140.2, 147.1, 166.4, and 207.7. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~16~H~18~BrO~3~Na, 361.0410; found, 361.0418.

### (*E*)-1-(2-Bromophenyl)-7-phenylhept-6-en-3-one (**17b**) {#sec4.5.5}

Yellow oil, (500.0 mg, 65%), Compound **17b** was prepared according to the procedure for Methodology B from ethyl (*E*)-2-(2-bromobenzyl)-3-oxo-7-phenylhept-6-enoate (**16b**) (940 mg, 2.23 mmol), LiCl (189 mg, 4.46 mmol), and H~2~O (40 mg, 2.23 mmol) in 5.5 mL of DMSO. The mixture was refluxed at 180 °C for 1 h. The crude product was purified by column chromatography, silica gel 60--200 mesh (30% DCM/hexane).^1^H NMR (CDCl~3~, 300 MHz): δ (ppm) 2.36--2.44 (m, 2H), 2.48--2.53 (m, 2H), 2.69 (t, 2H, *J* = 7.6 Hz), 2.94 (t, 2H, *J* = 7.6 Hz), 6.08 (dt, 1H, *J* = 16.0, 6.4 Hz), 6.31 (d, 1H, *J* = 16.0 Hz), 6.84--7.00 (m, 1H), 7.09--7.25 (m, 7H), and 7.43 (d, 1H, *J* = 7.8 Hz). ^13^C NMR (CDCl~3~, 75 MHz): δ (ppm) 27.4, 30.5, 42.6, 42.8, 124.4, 126.2, 127.8, 128.1, 128.7, 128.9, 130.8, 131.0, 133.0, 137.5, 140.5, and 208.9. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~19~H~19~BrONa, 365.0511; found, 365.0504.

### 1-(2-Bromophenyl)-7-methyloct-6-en-3-one (**17c**) {#sec4.5.6}

Yellow oil, (822.2 mg, 66%). Compound **17c** was prepared according to the procedure for Methodology B from methyl 2-(2-bromobenzyl)-7-methyl-3-oxooct-6-enoate (**16c**) (1500 mg, 4.25 mmol), LiCl (360 mg, 8.50 mmol), and H~2~O (76 mg, 4.25 mmol) in 11 mL of DMSO. The mixture was refluxed at 170 °C for 1 h. The crude product was purified by column chromatography, silica gel 60--200 mesh (30% DCM/hexane). ^1^H NMR (CDCl~3~, 300 MHz): δ (ppm) 1.60 (s, 3H), 1.66 (s, 3H), 2.25 (m, 2H), 2.42 (t, 2H, *J* = 7.1 Hz), 2.73 (t, 2H, *J* = 7.6 Hz), 3.00 (t, 2H, *J* = 7.6 Hz), 5.04 (t, 1H, *J* = 7.2 Hz), 7.02--7.08 (m, 1H), 7.21--7.26 (m, 2H), 7.21--7.26 (m, 2H), and 7.51 (d, 1H, *J* = 7.8 Hz). ^13^C NMR (CDCl~3~, 75 MHz): δ (ppm) 17.9, 22.8, 25.9, 30.6, 42.7, 43.1, 122.9, 124.5, 127.8, 128.1, 130.9, 133.1, 140.6, and 209.7. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~15~H~19~BrONa, 295.0712; found, 295.0708.

### Ethyl (*E*)-8-(2-Iodophenyl)-6-oxooct-2-enoate (**17d**) {#sec4.5.7}

Yellow oil, (38 mg, 50%). Compound **17d** was prepared according to the procedure for Methodology A from 1-ethyl 8-methyl (*E*)-7-(2-iodobenzyl)-6-oxooct-2-enedioate (**16d**) (75 mg, 0.17 mmol), LiCl (32 mg, 0.74 mmol), silica gel (68 mg), and DMF (25 μL). The vial was sealed and heated at 120 °C, 200 W for 10 min. The crude product was purified by column chromatography, silica gel 70--230 mesh (11--14% ethyl acetate/hexane). ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.31 (t, 3H, *J* = 7.2 Hz), 2.47--2.63 (m, 3H), 2.72--2.78 (m, 2H), 2.86--3.21 (m, 3H), 4.21 (q, 2H, *J* = 2.0 Hz), 5.85 (d, 1H, *J* = 18.6 Hz), 6.84--6.98 (m, 2H), 7.24--7.31 (m, 2H), and 7.84 (d, 1H, *J* = 7.0 Hz). Other spectroscopic data were previously reported in the literature.^[@ref14]^

### (*E*)-1-(2-Iodophenyl)-7-phenylhept-6-en-3-one (**17e**) {#sec4.5.8}

Yellow solid, mp 62--64 °C, (700 mg, 92%). Compound **17e** was prepared according to the procedure for Methodology A from methyl (*E*)-2-(2-iodobenzyl)-3-oxo-7-phenylhept-6-enoate (**16e**) (900 mg, 1.96 mmol), LiCl (350 mg, 8.04 mmol), silica gel (780 mg), and DMF (50 μL). The vial was sealed and heated at 135 °C, 200 W for 8 min. The crude product was purified by column chromatography, silica gel 70--230 mesh (12--14% ethyl acetate/hexane, 1% gradient). ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 2.39--2.44 (m, 2H), 2.50--2.53 (m, 2H), 2.65--2.69 (m, 2H), 2.91--2.95 (m, 2H), 6.06--6.14 (m, 1H), 6.32 (d, 1H, *J* = 15.8 Hz), 6.78--6.82 (m, 1H), 7.05--7.25 (m, 7H), and 7.70--7.76 (m, 1H). Other spectroscopic data were previously reported in the literature.^[@ref14]^

### 1-(2-Iodophenyl)-7,7-diphenylhept-6-en-3-one (**17g**) {#sec4.5.9}

Yellow oil, (97 mg, 72%). Compound **17g** was prepared according to the procedure for Methodology A from methyl 2-(2-iodobenzyl)-3-oxo-7,7-diphenylhept-6-enoate (**16g**) (150 mg, 0.30 mmol), LiCl (51 mg, 1.20 mmol), silica gel (200 mg), and DMF (25 μL). The vial was sealed and heated at 105 °C, 200 W for 8 min. The crude product was purified by column chromatography, silica gel 70--230 mesh (10--12% ethyl acetate/hexane, 1% gradient). ^1^H RMN (CDCl~3~): δ (ppm) 2.29--2.35 (m, 2H), 2.43--2.46 (m, 2H), 2.59--2.62 (m, 2H), 2.87--2.91 (m, 2H), 5.92--5.96 (m, 1H), and 7.07--7.30 (m, 14H). ^13^C RMN (CDCl~3~): δ (ppm) 24.2, 34.9, 42.8, 42.9, 100.2, 127.1, 127.2, 127.3, 127.7, 128.1, 128.1, 128.3, 128.5, 129.7, 129.8, 130.1, 139.6, 139.8, 142.4, 142.8, 143.6, and 208.7. HRMS (ESI-TOF) *m*/*z*: \[M + K\]^+^ calcd for C~25~H~23~IOK, 505.0431; found, 505.0436.

### (*E*)-7-(4-Chlorophenyl)-1-(2-iodophenyl)hept-6-en-3-one (**17f**) {#sec4.5.10}

Yellow oil, (280 mg, 90%). Compound **17f** was prepared according to the procedure for Methodology A from methyl (*E*)-7-(4-chlorophenyl)-2-(2-iodobenzyl)-3-oxohept-6-enoate (**16f**) (360 mg, 0.74 mmol), LiCl (130 mg, 3.01 mmol), silica gel (300 mg), and DMF (50 μL). The vial was sealed and heated at 135 °C, 200 W for 11 min. The crude product was purified by column chromatography, silica gel 70--230 mesh (15% ethyl acetate/hexane). ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 2.51--2.55 (m, 2H), 2.63 (t, 2H, *J* = 7.2, 7.0 Hz), 2.78 (t, 2H, *J* = 7.8, 7.6 Hz), 3.04 (t, 2H, *J* = 7.6 Hz), 6.19 (dt, 1H, *J* = 6.8 Hz), 6.38 (d, 1H, *J* = 15.8 Hz), 6.89--6.94 (m, 1H), 7.25--7.35 (m, 7H), and 7.83 (d, 1H, *J* = 7.8 Hz). Other spectroscopic data were previously reported in the literature.^[@ref14]^

### (*E*)-1-(2-Iodophenyl)-7-(4-nitrophenyl)hept-6-en-3-one (**17h**) {#sec4.5.11}

Yellow solid, mp 62--64 °C (94 mg, 60%). Compound **17h** was prepared according to the procedure for Methodology A from methyl (*E*)-2-(2-iodobenzyl)-7-(4-nitrophenyl)-3-oxohept-6-enoate (**16h**) (180 mg, 0.36 mmol), LiCl (66 mg, 1.56 mmol), silica gel (140 mg), and DMF (25 μL). The vial was sealed and heated at 120 °C, 200 W for 9 min. The crude product was purified by column chromatography, silica gel 70--230 mesh (80% DCM/hexane). ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 2.55--2.58 (m, 2H), 2.63 (d, 2H, *J* = 6.3 Hz), 2.77 (t, 2H, *J* = 7.7 Hz), 3.02 (t, 2H, *J* = 7.7 Hz), 6.39 (dt, 1H, *J* = 6.3 Hz), 6.47 (d, 1H, *J* = 16.1 Hz), 6.87--6.91 (m, 1H), 7.26 (d, 2H, *J* = 6.3 Hz), 7.44 (d, 2H, *J* = 8.8 Hz), 7.81 (d, 1H, *J* = 7.8 Hz), and 8.15 (d, 2H, *J* = 8.8 Hz). Other spectroscopic data were previously reported in the literature.^[@ref14]^

### (*E*)-1-Phenyldec-1-en-9-yn-5-one (**17i**) {#sec4.5.12}

Yellow oil, (267 mg, 73%). Compound **17k** was prepared according to the procedure for Methodology A from methyl 2-(3-butyn-1-yl)-3-oxo-7-phenyl-hepta-6-noate (**16i**) (460 mg, 1.62 mmol), LiCl (285 mg, 6.60 mmol), silica gel (2600 mg), and DMF (50 μL). The vial was sealed and heated at 105 °C, 200 W for 12 min. The crude product was purified by column chromatography, silica gel 70--230 mesh (10--12% ethyl acetate/hexane, 1% gradient). ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.81--1.88 (m, 2H), 1.88 (t, 1H, *J* = 2.6 Hz), 2.16 (td, 2H, *J*~1~ = 6.8 Hz, *J*~2~ = 2.7 Hz), 2.50--2.56 (m, 2H), 2.61--2.68 (m, 4H), 6.19--6.26 (m, 1H), 6.43--6.33 (d, 1H, *J* = 15.8 Hz), 7.22--7.25 (m, 1H), and 7.32--7.38 (m, 4H). ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 17.8, 22.2, 27.2, 41.2, 42.4, 69.1, 83.6, 126.1, 127.1, 128.5, 128.9, 130.8, 137.4 (Cq), and 209.4. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^calcd for C~16~H~18~Ona, 249.1255; found, 249.1257.

### 1,1-Diphenyldec-1-en-9-yn-5-one (**17j**) {#sec4.5.13}

Yellow oil, (100 mg, 60%). Compound **17j** was prepared according to the procedure for Methodology A from methyl 2-(3-butyn-1-yl)-3-oxo-7,7-diphenylhepte-6-noate (**16j**) (200 mg, 0.55 mmol), LiCl (107 mg, 2.30 mmol), silica gel (950 mg), and DMF (50 μL). The vial was sealed and heated at 105 °C, 200 W for 12 min. The crude product was purified by column chromatography, silica gel 230--400 mesh (6--10% ethyl acetate/hexane, 1% gradient). ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.63--1.73 (m, 2H), 1.84 (t, 2H, *J* = 2.6 Hz), 1.97 (s, 1H), 2.13 (td, 2H, *J*~1~ = 6.8 Hz, *J*~2~ = 2.7 Hz), 2.43--2.47 (m, 2H), 2.54--2.59 (m, 4H), 5.95 (t, 1H, *J* = 7.4 Hz), and 7.20--7.43 (m, 10H). ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 17.8, 22.2, 24.2, 41.1, 42.9, 69.1, 83.6, 127.1, 127.1, 127.3, 127.7, 128.1, 128.3, 139.8, 142.4, 142.8, and 209.5. HRMS (ESI-TOF) *m*/*z*: \[M + K\]^+^ calcd for C~22~H~22~OK, 341.1308; found, 341.1310.

### 8-(2-Iodophenyl)-6-oxooct-2-enenitrile (**17k**) {#sec4.5.14}

Yellow oil, *E*,*Z* Isomers (35 mg, 47%). Compound **17k** was prepared according to the procedure for Methodology A from methyl 7-cyano-2-(2-iodobenzyl)-3-oxohept-6-enoate (**16k**) (87 mg, 0.22 mmol), LiCl (37 mg, 0.88 mmol), and H~2~O (10 mg, 0.54 mmol) in 2 mL of DMF. The vial was sealed and heated at 135 °C, 205 W for 50 s. The crude product was purified by column chromatography, silica gel 70--230 mesh (18% ethyl acetate/hexane, 2% gradient). ^1^H NMR (CDCl~3~, 400 MHz), *E*,*Z* isomers: δ (ppm) 2.49--2.80 (m, 12H), 3.01 (t, 4H, *J* = 8.0 Hz), 5.34 (d, 2H, *J* = 14.0, 12.0 Hz), 6.51 (dt, 1H, *J* = 11.0, 8.0 Hz), 6.67 (dt, 1H, *J* = 16.0, 7.0 Hz), 6.91 (t, 2H, *J* = 8.0 Hz), 7.21--7.30 (m, 4H), and 7.82 (d, 2H, *J* = 8.0 Hz). ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 25.7, 25.9, 34.7, 40.2, 40.7, 42.6, 42.7, 100.1, 100.4, 100.9, 117.1, 128.2, 128.5, 129.7, 139.6, 143.1, 153.2, 153.9, 206.9, and 207.1. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~14~H~14~INONa, 362.0018; found, 362.0017.

General Procedure for Synthesis of β-Ketoesters **16a--k** {#sec4.6}
----------------------------------------------------------

To a suspension of potassium *tert*-butoxide or sodium hydride (1.00 equiv) in anhydrous THF (∼0.33 M) under argon atmosphere, the corresponding β-ketoester (1.00 equiv) was added dropwise. The reaction mixture was stirred for 10 min, and alkyl bromide (1.00--1.05 equiv) was added slowly. The stirring continued for 12 h at room temperature, with monitoring by TLC. Then, the reaction mixture was quenched with brine, extracted with ethyl acetate, the organic layer dried over MgSO~4~ or Na~2~SO~4~, and filtered. Finally, the solvent removed and the product was isolated by column chromatography.

### 1-Ethyl 8-Methyl (*E*)-7-(2-Bromobenzyl)-6-oxooct-2-enedioate (**16a**) {#sec4.6.1}

Yellow oil, (1640 mg, 53%). Compound **14a** was prepared according to the general procedure from methyl 2-(2-bromobenzyl)-3-oxobutanoate (**11**) (2200 mg, 7.75 mmol), potassium *tert*-butoxide (1000 mg, 7.75 mmol), methyl 4-bromo-2-butenoate (1.6 mL, 8.50 mmol), and THF (26 mL). The crude product was purified by column chromatography, silica gel 60--200 mesh (30% DCM/hexane). ^1^H NMR (CDCl~3~, 300 MHz): δ (ppm) 1.28 (t, 3H, *J* = 7.2 Hz), 2.43--2.50 (m, 2H), 2.54--2.59 (m, 1H), 2.92--3.04 (m, 3H), 3.62 (t, 1H, *J* = 7.2 Hz), 3.68 (s, 3H), 4.17 (q, 2H, *J* = 7.2 Hz), 5.81 (d, 1H, *J* = 15.6 Hz), 6.80 (dt, 1H, *J* = 15.6, 6.5 Hz), 7.03--7.09 (m, 1H), 7.22 (d, 2H, *J* = 4.2 Hz), and 7.51 (d, 1H, *J* = 7.8 Hz). ^13^C NMR (CDCl~3~, 75 MHz): δ (ppm) 14.7, 30.5, 30.6, 42.4, 53.1, 57.7, 60.8, 125.0, 124.6, 128.0, 128.5, 131.1, 133.2, 140.1, 144.2, 166.3, 169.2, and 202.7. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~18~H~21~BrO~5~, 419.0465; found, 419.0470.

### Ethyl (*E*)-2-(2-Bromobenzyl)-3-oxo-7-phenylhept-6-enoate (**16b**) {#sec4.6.2}

Yellow oil, (1070 mg, 71%). Compound **16b** was prepared according to the general procedure from (*E*)-ethyl 3-oxo-7-phenyl-6-heptenoate (**12**) (910 mg, 3.63 mmol), potassium *tert*-butoxide (480 mg, 3.63 mmol), ethyl 4-bromo-2-butenoate (0.93 mL, 3.63 mmol), and THF (12 mL). The crude product was purified by column chromatography, silica gel 60--200 mesh (30% DCM/hexane). ^1^H NMR (CDCl~3~, 300 MHz): δ (ppm) 1.09 (t, 3H, *J* = 6.9 Hz), 2.35 (dt, 2H, *J* = 6.9, 6.6 Hz), 2.48 (dt, 1H, *J* = 17.4, 6.6 Hz), 2.68 (dt, 1H, *J* = 17.4, 6.6 Hz), 3.19 (d, 2H, *J* = 7.8 Hz), 3.94 (t, 1H, *J* = 7.5 Hz), 4.03 (q, 2H, *J* = 7.2 Hz), 6.02 (dt, 1H, *J* = 16.0, 6.9 Hz), 6.27 (d, 1H, *J* = 16.0 Hz), 6.87 (t, 1H, *J* = 7.5 Hz), 7.05--7.20 (m, 7H), and 7.42 (d, 1H, *J* = 7.8 Hz). ^13^C NMR (CDCl~3~, 75 MHz): δ (ppm) 14.2, 26.9, 34.5, 42.6, 58.2, 61.7, 124.6, 126.1, 127.2, 127.6, 128.4, 128.6, 128.7, 131.1, 131.9, 133.0, 137.4, 137.5, 168.8, and 203.8. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~22~H~23~BrO~3~Na, 437.0728; found: 437.0721.

### Methyl 2-(2-Bromobenzyl)-7-methyl-3-oxooct-6-enoate (**16c**) {#sec4.6.3}

Yellow oil, (1860 mg, 68%). Compound **16c** was prepared according to the general procedure from (*E*) methyl 7-methyl-3-oxo-6-octenoate (**13**) (1500 mg, 7.74 mmol), potassium *tert*-butoxide (1060 mg, 8.96 mmol), ethyl 4-bromo-2-butenoate (2070 mg, 8.15 mmol), and THF (27 mL). The crude product was purified by column chromatography, silica gel 60--200 mesh (30% DCM/hexane). ^1^H NMR (CDCl~3~, 300 MHz): δ (ppm) 1.76 (s, 3H), 1.84 (s, 3H), 2.35--2.42 (m, 2H), 2.40 (dt, 1H, *J* = 17.1, 7.2 Hz), 2.59 (dt, 1H, *J* = 17.1, 7.4 Hz), 3.46 (d, 2H, *J* = 7.8 Hz), 3.87 (s, 3H), 4.20 (t, 1H, *J* = 7.2 Hz), 5.16 (t, 1H, *J* = 7.2 Hz), 7.25--7.30 (m, 1H), 7.36--7.46 (m, 2H), and 7.72 (d, 1H, *J* = 7.5 Hz). ^13^C NMR (CDCl~3~, 75 MHz): δ (ppm) 17.8, 22.3, 25.8, 34.6, 43.2, 52.6, 58.0, 122.4, 124.6, 127.7, 128.7, 131.9, 133.1, 137.5, 169.4, and 204.3. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ calcd for C~18~H~24~BrO~3~, 353.0771; found, 353.0770.

### 1-Ethyl 8-Methyl (*E*)-7-(2-Iodobenzyl)-6-oxooct-2-enedioate (**16d**) {#sec4.6.4}

Yellow oil, (1140 mg, 57%). Compound **16d** was prepared according to the general procedure from (*E*) methyl 5-(2-iodophenyl)-3-oxopentanoate (**14**) (1400 mg, 4.16 mmol), potassium *tert*-butoxide (500 mg, 4.37 mmol), ethyl 4-bromo-2-butenoate (1180 mg, 4.58 mmol), and THF (13 mL). The crude product was purified by column chromatography, silica gel 230--400 mesh (30--40% diethyl ether/hexane, 10% gradient) and then (15--16% ethyl acetate/hexane, 1% gradient). ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.30 (t, 3H, *J* = 7.2 Hz), 2.74--2.87 (m, 3H), 2.94--3.07 (m, 3H), 3.64 (t, 1H, *J* = 7.3 Hz), 3.72 (s, 3H), 4.20 (q, 2H, *J* = 7.0 Hz), 5.88 (d, 1H, *J* = 15.6 Hz), 6.80--6.88 (m, 1H), 6.90--6.94 (m, 1H), 7.23--7.31 (m, 2H), and 7.83 (d, 1H, *J* = 7.8 Hz). Other spectroscopic data were previously reported in the literature.^[@ref14]^

### Methyl (*E*)-2-(2-Iodobenzyl)-3-oxo-7-phenylhept-6-enoate (**16e**) {#sec4.6.5}

Yellow oil, (2470 mg, 77%). Compound **16e** was prepared according to the general procedure from methyl (*E*)-3-oxo-7-phenylhept-6-enoate (**12**) (1680 mg, 7.16 mmol), potassium *tert*-butoxide (870 mg, 7.59 mmol), methyl 4-bromo-2-butenoate (2120 mg, 7.88 mmol), and THF (22 mL). The crude product was purified by column chromatography, silica gel 70--230 mesh (30% DCM/hexane).^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 2.47 (q, 2H, *J* = 6.9 Hz), 2.56--2.64 (m, 1H), 2.77--2.85 (m, 1H), 3.31 (d, 2H, *J* = 7.5 Hz), 3.70 (s, 3H), 4.06 (t, 1H, *J* = 7.4 Hz), 6.14 (dt, 1H, *J* = 15.8, 6.9 Hz), 6.40 (d, 1H, *J* = 16.1 Hz), 6.89--6.94 (m, 1H), 7.21--7.34 (m, 8H), and 7.83 (d, 1H, *J* = 7.8 Hz). Other spectroscopic data were previously reported in the literature.^[@ref14]^

### Methyl (*E*)-7-(4-Chlorophenyl)-2-(2-iodobenzyl)-3-oxohept-6-enoate (**16f**) {#sec4.6.6}

Yellow oil, (460 mg, 52%). Compound **16f** was prepared according to the general procedure from methyl 5-(2-iodophenyl)-3-oxopentanoate (**14**) (618 mg, 1.84 mmol), sodium hydride (80 mg, 1.94 mmol), (*E*)-1-chloro-4-(3-chloroprop-1-en-1-yl)benzene (370 mg, 1.94 mmol), and THF (3.7 mL). The mixture was refluxed for 18 h, the product was purified by column chromatography, silica gel 70--230 mesh (10--16% ethyl acetate/hexane, 2% gradient). ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 2.79 (td, 2H, *J* = 7.2, 1.0 Hz), 2.82--2.88 (m, 1H), 2.96 (dd, 1H, *J* = 6.6, 6.4 Hz), 3.02--3.07 (m, 2H), 3.67 (t, 1H, *J* = 7.3 Hz), 3.74 (s, 3H), 6.11 (dt, 1H, *J* = 7.4, 7.2 Hz), 6.43 (d, 1H, *J* = 15.8 Hz), 6.90--6.94 (m, 1H), 7.24--7.31 (m, 6H), and 7.83 (d, 1H, *J* = 8.0 Hz). Other spectroscopic data were previously reported in the literature.^[@ref14]^

### Methyl 2-(2-Iodobenzyl)-3-oxo-7,7-diphenylhept-6-enoate (**16g**) {#sec4.6.7}

Yellow oil, (230 mg, 58%). Compound **16g** was prepared according to the general procedure from (*E*) methyl 7-methyl-3-oxo-7,7-diphenylhepte-6-noate (**15**) (230 mg, 0.80 mmol), potassium *tert*-butoxide (91 mg, 0.85 mmol), 1-(bromomethyl)-2-iodobenzene (249 mg, 0.88 mmol), and THF (2.1 mL). The crude product was purified by column chromatography, silica gel 230--400 mesh (10--13% ethyl acetate/hexane, 1% gradient). ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 2.38 (q, 2H, *J* = 7.3 Hz), 2.49--2.57 (m, 1H), 2.70--2.78 (m, 1H), 3.27--3.29 (m, 2H), 3.69 (s, 3H), 4.02 (t, 1H, *J* = 7.5 Hz), 5.98 (t, 1H, *J* = 7.4 Hz), and 7.16--7.42 (m, 14H). ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 23.8, 38.7, 43.2, 52.5, 58.0, 100.3, 127.1, 127.2, 127.3, 128.1, 128.3, 128.5, 128.7, 129.8, 130.9, 139.7, 140.5, 142.4, 142.9, 169.1, and 203.7. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~27~H~25~IO~3~Na, 547.0746; found, 547.0749.

### Methyl (*E*)-2-(2-Iodobenzyl)-7-(4-nitrophenyl)-3-oxohept-6-enoate (**16h**) {#sec4.6.8}

Yellow oil, (250 mg, 34%). Compound **16h** was prepared according to the general procedure from methyl 5-(2-iodophenyl)-3-oxopentanoate (**14**) (490 mg, 1.48 mmol), potassium *tert*-butoxide (200 mg, 1.62 mmol), (*E*)-1-(3-bromoprop-1-en-1-yl)-4-nitrobenzene (390 mg, 1.62 mmol), and THF (4.9 mL). The product was purified by column chromatography, silica gel 70--230 mesh (20% ethyl acetate/hexane). ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 2.80--2.88 (m, 3H), 2.97 (dd, 1H, *J* = 8.53, 6.02 Hz), 3.02--3.06 (m, 2H), 3.69 (t, 1H, *J* = 7.4 Hz), 3.74 (s, 3H), 6.32 (dt, 1H, *J* = 15.8, 7.37 Hz), 6.53 (d, 2H, *J* = 15.8 Hz), 6.88--6.93 (m, 1H), 7.25--7.26 (m, 1H), 7.44 (d, 2H, *J* = 8.8 Hz), 7.81 (d, 1H, *J* = 7.5 Hz), and 8.17 (d, 2H, *J* = 8.8 Hz). Other spectroscopic data were previously reported in the literature.^[@ref14]^

### Methyl (*E*)-2-(But-3-yn-1-yl)-3-oxo-7-phenylhept-6-enoate (**16i**) {#sec4.6.9}

Yellow oil, (128 mg, 48%). Compound **16i** was prepared according to the general procedure from methyl 3-oxophenylhepta-6-nonate (**12**) (570 mg, 2.50 mmol), sodium hydride (108 mg, 2.70 mmol), 4-iodo-1-butyne (608 mg, 2.70 mmol), and THF (5.0 mL). The product was purified by column chromatography, silica gel 70--230 mesh (13--16% ethyl acetate/hexane, 1% gradient). ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.92 (t, 1H, *J* = 2.5 Hz), 2.08 (s, 1H), 2.02--2.03 (m, 1H), 2.21 (s, 1H), 2.27--2.31 (m, 1H), 2.45 (s, 1H), 2.51--2.87 (m, 4H), 3.23--3.29 (m, 1H), 3.75--3.84 (m, 3H), 6.17--6.27 (m, 1H), 6.34 (d, 1H, *J* = 15.8 Hz), and 7.22--7.37 (m, 5H). ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 16.4, 26.5, 26.9, 42.1, 52.6, 57.0, 69.9, 82.6, 126.1, 127.2, 128.5, 131.1, 129.6, 169.7, and 203.9. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~18~H~20~O~3~Na, 307.1310; found, 307.1308.

### Methyl 2-(But-3-yn-1-yl)-3-oxo-7,7-diphenylhept-6-enoate (**16j**) {#sec4.6.10}

Yellow oil, (745 mg, 44%). Compound **16j** was prepared according to the general procedure from methyl 3-oxo-7,7-diphenylhepta-6-nonate (**15**) (1550 mg, 4.92 mmol), sodium hydride (217 mg, 5.42 mmol), 4-iodo-1-butyne (1027 mg, 5.42 mmol), and THF (10.0 mL). The product was purified by column chromatography, silica gel 70--230 mesh (13--16% ethyl acetate/hexane, 1% gradient). ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 1.85 (t, 1H, *J* = 2.6 Hz), 1.91--1.97 (m, 2H), 2.12 (dt, 2H, *J* = 6.8, 2.3 Hz), 2.26--2.34 (q, 2H), 2.55--2.72 (m, 2H), 3.62 (s, 3H), 3.61--3.67 (m, 1H), 5.92 (dt, 1H, *J* = 7.4, 3.7 Hz), and 7.09--7.32 (m, 10H). ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 16.4, 24.0, 26.5, 42.6, 52.5, 57.0, 70.0, 82.5, 127.1, 127.1, 127.2, 127.2, 128.1, 128.3, 129.8, 139.8, 142.4, 143.1, 169.7, and 204.0. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~24~H~24~O~3~Na, 383.1623; found, 383.1624.

### Methyl-5-cyano-2-(3-(2-iodophenyl)propanoyl)pent-4-enoate (**16k**) {#sec4.6.11}

Yellow oil, (56 mg, 36%). Compound **16k** was prepared according to the general procedure from methyl 5-(2-iodophenyl)-3-oxopentanoate (**14**) (130 mg, 0.45 mmol), potassium *tert*-butoxide (56 mg, 0.50 mmol), (*E*,*Z*)-4-bromobut-2-enenitrile (80 mg, 0.54 mmol), and THF (1.20 mL). The product was purified by column chromatography, silica gel 70--230 mesh (5--10% ethyl acetate/hexane, 1% gradient). ^1^H NMR (CDCl~3~, 400 MHz), *E*,*Z* isomers: δ (ppm) 2.71--2.85 (m, 4H), 2.90--3.04 (m, 8H), 3.58 (t, 1H, *J* = 7.0 Hz), 3.64 (t, 1H, *J* = 7.0 Hz), 3.72 (s, 6H), 5.36--5.40 (m, 2H), 6.46 (dt, 1H, *J* = 11.0, 8.0 Hz), 6.58 (dt, 1H, *J* = 16.0, 7.0 Hz), 6.88--6.93 (m, 2H), 7.21--7.30 (m, 4H), and 7.82 (d, 2H, *J* = 8.0 Hz). ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 29.6, 31.1, 34.5, 42.1, 42.3, 52.8, 52.9, 56.8, 56.9, 99.9, 100.1, 102.1, 102.7, 115.2, 116.7, 128.2, 128.3, 128.5, 129.8, 139.6, 142.7, 142.8, 150.1, 150.8, 168.5, 201.6, and 201.8. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~16~H~16~NIO~3~Na, 420.0073; found, 420.0074.

General Procedure for Synthesis of β-Ketoesters **11--15** {#sec4.7}
----------------------------------------------------------

A suspension of sodium hydride (1.4 mmol) was stirred with a minimum amount of anhydrous THF for 10 min, the suspension was stopped, and the THF was removed. After that, a new amount of anhydrous THF (∼0.37 M) was added and cooled to 0° C. Ethyl acetoacetate was added dropwise (1.4 mmol) and the mixture was stirred, then *n*-butyllithium was added (2.5 M, 1.4 mmol) at 0 °C followed by the alkyl halide (1.00 mmol) with stirring for 1.5 h until reaching room temperature. Finally, the reaction was quenched with a saturated solution of NH~4~Cl and extracted with diethyl ether, the organic layer was dried over MgSO~4~ or Na~2~SO~4~, filtered, and the solvent was removed.^[@cit12a],[@cit12b]^

### Methyl 5-(2-Bromophenyl)-3-oxopentanoate (**11**) {#sec4.7.1}

Yellow oil, (5964 mg, 65%). Compound **11** was prepared according to the general procedure from methyl acetoacetate (3.50 mL, 32.1 mmol), sodium hydride (1540 mg, 38.5 mmol), *n*-butyllithium (15.4 mL, 38.5 mmol) and 1-(bromomethyl)-2-bromobenzene (9000 mg, 35.3 mmol), and THF (21 mL). The product was purified by column chromatography, silica gel 60--200 mesh (30% DCM/hexane). ^1^H NMR (CDCl~3~, 300 MHz): δ (ppm) 2.86--2.92 (m, 2H), 2.99--3.05 (m, 2H), 3.46 (s, 2H), 3.71 (s, 3H), 7.04 (m, 1H), 4.04--7.09 (m, 2H), and 7.51 (d, 1H, *J* = 7.8 Hz). ^13^C NMR (CDCl~3~, 75 MHz): δ (ppm) 30.2, 42.9, 49.2, 52.5, 124.4, 127.8, 128.2, 130.8, 139.9, 167.6, and 201.4. Other spectroscopic data were previously reported in the literature.^[@ref19]^

### Methyl (*E*)-3-Oxo-7-phenylhept-6-enoate (**12**) {#sec4.7.2}

Yellow oil, (1680 mg, 75%). Compound **12** was prepared according to the general procedure from methyl acetoacetate (1580 mg, 13.5 mmol), sodium hydride (540 mg, 13.5 mmol), *n*-butyllithium (5.4 mL, 13.5 mmol) and (*E*)-(3-bromoprop-1-en-1-yl)benzene (2000 mg, 9.64 mmol), and THF (36.5 mL). The product was purified by column chromatography, silica gel 70--230 mesh (12--15% ethyl acetate/hexane, 1% gradient).^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 2.50 (dd, 2H, *J* = 6.8, 7.3, 7.0 Hz), 2.72 (t, 2H, *J* = 8.0 Hz), 3.46 (s, 2H), 3.72 (s, 3H), 6.17 (dt, 1H, *J* = 16.0, 7.0 Hz), 6.41 (d, 1H, *J* = 16.0 Hz), 7.17--7.21 (m, 1H), and 7.26--7.33 (m, 5H). Other spectroscopic data were previously reported in the literature.^[@ref20]^

### Methyl 7-Methyl-3-oxooct-6-enoate (**13**) {#sec4.7.3}

Yellow pale oil, (1680 mg, 75%). Compound **13** was prepared according to the general procedure from methyl acetoacetate (2152 mg, 18.3 mmol), sodium hydride (880 mg, 22.0 mmol), *n*-butyllithium (8.8 mL, 21.2 mmol) and 1-bromo-3-methylbut-2-ene (3612 mg, 24.2 mmol), and THF (12 mL). The product was purified by column chromatography, silica gel 70--230 mesh (5--10% ethyl acetate/hexane, 1% gradient). ^1^H NMR (CDCl~3~, 300 MHz): δ (ppm) 1.61 (s, 3H), 1.68 (s, 3H), 2.22--2.31 (m, 2H), 2.56 (t, 2H, *J* = 7.2 Hz), 3.45 (s, 2H), 3.73 (s, 3H), and 5.06 (t, 1H, *J* = 7.2 Hz). ^13^C NMR (CDCl~3~, 75 MHz): δ (ppm) 18.0, 22.6, 26.0, 43.4, 49.5, 52.6, 122.6, 133.4, 168.0, and 202.7. HRMS (ESI) calcd for C~10~H~16~NO~3~ \[(M + Na^+^)\], 207.0992; found, 207.0992.

### Methyl 5-(2-Iodophenyl)-3-oxopentanoate (**14**) {#sec4.7.4}

Yellow oil, (1510 mg, 79%). Compound **14** was prepared according to the general procedure from methyl acetoacetate (970 mg, 8.36 mmol), sodium hydride (330 mg, 8.36 mmol), *n*-butyllithium (3.3 mL, 8.36 mmol) and 1-(bromomethyl)-2-iodobenzene (1790 mg, 5.97 mmol), and THF (23 mL). The product was purified by column chromatography, silica gel 70--230 mesh (12--15% ethyl acetate/hexane, 1% gradient). ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 2.85 (dd, 2H, *J* = 8.0 Hz), 3.00 (dd, 2H, *J* = 8.0 Hz), 3.46 (s, 2H), 3.71 (s, 3H), 6.88 (ddd, 1H, *J* = 7.4 Hz), 7.24 (m, 2H), and 7.79 (dd, 1H, *J* = 8.0 Hz). Other spectroscopic data were previously reported in the literature.^[@ref21]^

### Methyl 3-Oxo-7,7-diphenylhept-6-enoate (**15**) {#sec4.7.5}

Yellow oil, (223 mg, 32%). Compound **15** was prepared according to the general procedure from methyl acetoacetate (420 mg, 3.60 mmol), sodium hydride (143 mg, 3.60 mmol), *n*-butyllithium (1.4 mL, 3.60 mmol) and (3-bromoprop-1-ene-1,1-diyl)dibenzene (700 mg, 2.60 mmol), and THF (11 mL). The product was purified by column chromatography, silica gel 70--230 mesh (12--15% ethyl acetate/hexane, 1% gradient). ^1^H NMR (CDCl~3~, 400 MHz): δ (ppm) 2.52--2.57 (m, 2H), 2.43--2.48 (m, 2H), 2.68--2.71 (m, 2H), 3.45 (s, 2H), 3.75 (s, 3H), 6.05--6.09 (m, 1H), and 7.19--7.43 (m, 10H). ^13^C NMR (CDCl~3~, 100 MHz): δ (ppm) 23.9, 43.0, 49.0, 52.4, 127.1, 127.1, 127.2, 127.2, 128.2, 128.4, 129.8, 139.7, 142.3, 143.1, 167.6, and 201.8. Other spectroscopic data were previously reported in the literature.^[@ref22]^

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsomega.9b02515](https://pubs.acs.org/doi/10.1021/acsomega.9b02515?goto=supporting-info). ^1^H and ^13^C NMR spectra of all of the synthesized compounds, one spectrum NOESY-2D of the spirocyclic *trans*-**19b**, and one NOESY spectrum with selective protons couplings in the spirocyclic *trans*-**19e** ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02515/suppl_file/ao9b02515_si_001.pdf))
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